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Vesicular stomatitis virus (VSV) is the prototypic and best-studied member of 
the Rhabdoviridae.  Despite this, there remain many uncertainties regarding the exact 
process by which VSV enters host cells.  One proposed mechanism involves virus 
internalization into endosomes, followed by a two-step fusion reaction; initial fusion 
with internal vesicles of multivesicular endosomes followed by subsequent back-
fusion of these vesicles into the cytoplasm.  However, the biological rationale for this 
pathway remains obscure.  One feature of the internal vesicles of late endosomes is 
that they uniquely contain the lipid lysobisphosphatidic acid (LBPA).  Using a FRET-
based in vitro lipid mixing assay, we show that the presence of LBPA significantly 
increases the rate of VSV G-mediated membrane fusion.  The increased rate of lipid 
mixing was selective for VSV and was not evident when other viruses, such as 
influenza, were examined in the same assay.  These data provide a biological rationale 
for a two-step fusion reaction during VSV entry, and suggests that LBPA may 
preferentially affect the ability of VSV G (a class III viral fusion protein) to mediate 
lipid mixing during membrane fusion. 
 The Coronaviridae is a virus family with significant potential to negatively 
affect the human population.  An improvement in our understanding of the entry 
mechanism of these viruses could assist in the development of therapeutics.  Here we 
characterize a proposed fusion peptide in several members of the coronavirus family.  
 Our results show that this peptide is capable of promoting membrane fusion in a 
liposome based assay.  When the sequence of the hypothesized fusion peptide is 
manipulated, its ability to promote lipid mixing is abolished.  Additionally, we outline 
significant differences between the fusion peptides of several different coronavirus 
family members and postulate the effect these differences have on virus fusion.  Our 
results support the hypothesis that this region is in fact the fusion peptide for the 
coronavirus family.
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CHAPTER 1 
INTRODUCTION 
Viral Entry and Fusion 
 The initial interactions of a virus and host cell that ultimately allow  the 
completion of the virus replication cycle are commonly called virus entry [1].  These 
interactions typically begin with a binding event between the fusion protein of the 
virus and the surface of the host cell.  Viral fusion proteins are critical to this initial 
stage of the virus life cycle because they are responsible for receptor binding as well 
as the merging of the viral lipid membrane and the host cell lipid membrane in the 
case of enveloped viruses.   
Viral fusion proteins are divided into three classes based on their 
characteristics, as shown in Table 1.1.   
Table 1.1 Classification of viral fusion proteins (adapted from Weissenhorn et. al, 
FEBS Lett., 2007.) 
 
Class I fusion proteins are typified by the influenza hemagglutinin protein.  
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Class I fusion proteins are composed of mainly alpha helical secondary structure, and 
usually form trimers [2-4].  They require proteolytic processing of the protein in a 
position close to the fusion peptide which leaves the protein in a metastable state prior 
to fusion.  Fusion of class I fusion proteins can be triggered by receptor binding, low 
pH or a combination of the two.  In contrast to class I fusion proteins, a typical class II 
fusion protein is the Semliki Forest virus E1/E2 protein[2-4].  Structurally, they are 
mainly composed of β-sheet like structures and exist as dimers in their native form.  
Although proteolytic processing is required for them to attain a fusion active state, an 
accessory protein is cleaved rather than the fusion protein itself.  Additionally, low pH 
is the common mechanism of activation of class II fusion proteins.  Recently a third 
class of fusion proteins has been established and notably contains, vesicular stomatitis 
virus (VSV) G protein and herpes simplex virus-1 (HSV-1) gB protein [4-6].  They are 
unique among fusion proteins due to their structure which is composed of roughly 
equal components of α-helix and β-sheet, as well as other unique characteristics. 
 The first interaction between a virus and cell involves the binding of 
viral attachment proteins to specific cell surface receptors [7].  Viral receptors are 
defined as cell surfaced agents that directly bind with native virions and produce a 
biologic response [8].  Receptors can initiate conformational changes, activate 
signaling pathways, and/or promote endocytic internalization [1].  These receptors can 
be proteins, carbohydrates, or even lipids.  It has also been found that the initial 
binding of the receptor to a virus can induce a conformational change which allows 
binding to a second receptor, usually called a co-receptor.  The use of a co-receptor 
has been extensively studied for several viruses [9], most notably HIV  [10].  A third 
and less specific type of interaction is also utilized by viruses.  This interaction 
involves what is called an attachment factor which binds virus particles to the surfaced 
and concentrates them there [1].  Based on the importance of the receptor for the 
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initial interaction between the cell and the virus, it is easy to see that the distribution of 
the receptor on various tissues determines the cell tropism of the virus. 
 Subsequent to virus-receptor interaction, there are two possible 
methods of entry for the virus into the cell.  In the case of paramyxoviruses and other 
pH independent viruses, entry continues with direct fusion of the viral lipid membrane 
with the plasma membrane of the host cell which deposits the nucleocapsid into the 
cytoplasm.  Most RNA viruses replicate in the cytoplasm, but DNA viruses that fuse 
at the plasma membrane must replicate in the nucleus and their nucleocapsids are first 
transported before replication can begin.  For influenza, VSV and other pH dependent 
viruses, receptor interactions are used to trigger endocytosis.  Clathrin-mediated 
endocytosis is the most commonly used viral endocytic route [1], however clathrin-
independent virus entry has also been identified as shown in Figure 1.1.   
 
Figure 1.1 Entry mechanisms used by viruses (Marsh & Helenius, Cell, 2006.) 
As mentioned previously, it is common for viruses and other pathogens to 
hijack the essential cell endocytic pathway to gain access to the cell cytoplasm.  The 
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endocytic pathway normally serves to sort proteins and takes part in 
macromolecular/nutrient uptake/regulating signaling from receptors, and lysosome 
biogenesis [11].  The best understood mechanism of endocytosis is clathrin-mediated 
endocytosis [12], but other pathways are possible involving caveolae, polymorphous 
tubes and macropinosomes [13, 14].  In clathrin-mediated endocytosis, membrane 
proteins bind to cytosolic adaptors which are linked to the clathrin lattice.  Additional 
accessory proteins are used to promote curvature of the membrane and clathrin 
polymerization.  Finally, the vesicle is severed from the plasma membrane in a 
processed thought to be mediated by dynamin [15].  There are several ways by which 
clathrin-mediated endocytosis can be triggered.  One example involves short linear 
amino acid sequences present on the cytosolic tail of proteins such as YXXΦ and 
[DE]xxxLL motifs which can be recognized AP2, a clathrin adaptor protein [16].  
Another mechanism involves protein modification by ubiquitin which is recognized by 
the EPS15 and epsin clathrin adaptor proteins [17].  After uptake from the plasma 
membrane, a protein will arrive at an early endosome, followed by a late endosome, 
and ultimately be delivered to the trans-Golgi network (TGN), a lysosome or recycled 
back to the plasma membrane.  Efficient retrograde transport from endosomes to the 
TGN is limited to a specific set of proteins, of which the most is known about the 
acid-hydrolase receptors, transmembrane enzymes and SNAREs [18].  Although the 
retrograde-transport mechanism for most proteins is unknown, some information has 
been established regarding the transport of acid-hydrolase receptors.  It is believed that 
the process initiates with the budding of transport carriers from early or late 
endosomes involving a protein complex named a retromer [18], which travels to the 
TGN where it fuses.  It is possible that transport to the TGN of other proteins also 
involves components of this system.  Proteins are also transported from the early 
endosome to the lysosome for destruction.  The process of sorting proteins to the 
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lysosome begins in the late endosome.  Late endosomes contain intralumenal vesicles 
which are formed by the invagination of the limiting membrane of the endosome.  The 
sorting of cargo into these intraluminal vesicles, which is signaled by the 
ubiquitination of these proteins, dooms them to be degraded in the lysosome [12].  
Numerous hypotheses have been proposed regarding how  proteins are transferred 
from late endosomes to the lysosome [12].  Although the kiss-and-run [19] and hybrid 
compartment models [20, 21]  have the most experimental evidence behind them, 
more work must be done to conclusively determine this mechanism.  Finally, proteins 
can be taken up from the plasma membrane by the endocytic pathway and returned.   
This method of transport is necessary to maintain a balance of receptors at the cell 
surface and aid in absorption of macromolecules [11].  For many proteins “recycled” 
in this way, the mechanism of sorting is not fully understood.  One method used by the 
LDL receptor related protein LRP is the presence of a cytoplasmic tail motif NPxY 
which interacts with the sorting nexin protein SNX17 [11].  Another widely known 
protein the transferrin receptor (TfnR) is also recycled from the plasma membrane.  It 
is thought to use  “fast” recycling pathway in the early endosome [22].  From the  
complexity of the endosomal system and the vast variety of ways in which it is 
utilized, it is easy to see how it would be advantageous for pathogens to “borrow” the 
system. 
 At some point in the endocytic pathway, fusion between the viral lipid 
membrane and the endosomal membrane is triggered and the nucleocapsid is 
deposited into the cytoplasm.  Fusion and fission events also regularly occur in the cell 
under routine circumstances.   SNARE (SNAP receptors) proteins are the central 
mediators of these fusion events which are exemplified in the prior discussion of the 
endocytic pathway.  SNAREs bind SNAP (soluble NSF attachment proteins) and NSF 
(N-ethylmaleimide sensitive factor) [23].   
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Figure 1.2 A simplified diagram of the endocytic pathway (Seaman. Cell. Mol. 
Life Sci., 2008.) 
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SNAREs are typically type II membrane proteins of which the majority of the protein 
is exposed to the cytoplasm.  SNAREs are divided in to two groups, the v-SNARES 
which are found on the vesicles being transported and t-SNARES which are found on 
the target membrane [24].  Although there are many SNAREs and therefore a large 
number of combinations of SNAREs that could form complexes, only a small number 
can actually promote fusion .  In this way, SNAREs can provide specificity to the 
fusion reaction.  The initial step in vesicle-target fusion is an interaction involving a 
tethering protein and a Rab protein [25].  This interaction brings the SNARE proteins 
present on the two surfaces close enough together to form a SNARE-pin which 
consists of an assembly of parallel four-helix bundle of the SNARE protein and an SM 
(Sec1/Munc18-like) protein.  The “zipping up” of the four-helix bundle provides 
enough energy to pull the two membranes close enough to drive fusion.  One SNARE 
pin is sufficient to achieve hemifusion but at least three are required for full fusion 
[26]. After fusion has occurred, the complex ends up in a configuration called the cis-
SNARE complex, which can be reactivated in an ATP dependent manner with NSF.  
Although the details of the mechanism are different, SNARE complexes and viral 
fusion proteins act in a similar manner to destabilize membranes and  bring them close 
enough together to promote a fusion event [27].  
 The key component of the fusion protein which enables fusion is the 
fusion peptide [28].  The fusion peptide is the portion of the fusion protein that is 
inserted into the host cell membrane.  Not only does the insertion of the fusion peptide 
into the host cell membrane serve to bring the two membranes close enough to 
promote mixing, but they also alter the organization and structure of the lipid bilayers 
they are inserted into [29].   
 
 8 
Figure 1.3 Membrane fusion in the endocytic pathway, steps a-e (Wickner & 
Schekman, Nat. Struct. Mol. Biol., 2008.)  
 
 The work contained in this thesis examines several aspects of entry, 
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both receptor binding and fusion, for several viruses.  In chapter 2, a line of research 
examining the effect of membrane lipid composition on VSV fusion is examined.  
Characterization of a novel coronavirus fusion peptide is the topic of chapter 3.  
Finally, appendix 1 examines possible receptor interactions of influenza.  In the 
remainder of this introduction, I will attempt to lay a foundation for the understanding 
of these studies by providing a brief overview of what is currently known about the 
process of virus entry for each of the studied viruses.   
Vesicular Stomatitis Virus (VSV) 
 Vesicular stomatitis virus (VSV), Figure 1.4, is a member of the 
Rhabdoviridae [30].  As such, it is an enveloped virus and has a non-segmented , 
negative stranded RNA genome which encodes 5 proteins including a glycoprotein 
(G), matrix protein (M), phosphoprotein (P), large protein (L) and a nucleoprotein (N).  
Of key importance to VSV entry and fusion is the G protein which is responsible for 
receptor binding and fusion of the viral and host membrane which results in the 
delivery of the nucleocapsid to the cell cytoplasm.   
Figure 1.4 Schematic representation of Vesicular stomatitis virus (adapted from Dr. 
Ruth Collins with permission, personal communication). 
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 The X-ray crystal structures of the VSV G protein in its pre and post fusion 
forms were recently elucidated [31, 32].  This structure afforded many insights into the 
mechanism of the G protein and also established it as a member of a new class of 
fusion proteins as discussed previously[33].  One important revelation was the 
identification of bipartite fusion loops in contrast to a fusion peptide.  Mutagenesis 
experiments performed on the residues in these fusion loops show they are intolerant 
to manipulation [34].  Although the crystal structure has shed light into the 
mechanisms of G protein rearrangement upon exposure to low pH and the active 
fusion domain, the VSV receptor binding site and the identity of the receptor itself are 
still unknown. 
 An early attempt at the identification of the VSV receptor showed that cell 
membrane extracts were no longer inhibitory to VSV binding after being treated with 
phospholipase C but not after treatment with proteases, neuraminidase or heat [35].  
This initial observation led to the hypothesis that the receptor for VSV was a lipid.  
Additionally, the same investigators were able to show that when VSV was exposed to 
phosphatidylserine or liposomes containing phosphatidylserine VSV binding to cell 
surfaces was inhibited.  Since those observations, it has been observed that VSV G 
protein interacts with several other lipids besides phosphatidylserine.  Some initial 
studies used purified lipid and carbohydrate components to inhibit virus promoted 
cell-cell fusion [36].  In addition to phosphatidylserine, phosphatidylinositol, 
sphinogmyelin, cholesterol, and the ganglioside GM3 were able to inhibit VSV 
promoted cell-cell fusion.  Subsequent biochemical experiments utilizing isothermal 
titration calorimetry and atomic force microscopy confirmed the interaction between 
VSV G and phosphatidylserine and also suggested an interaction with cardiolipin and 
phosphatidylglycerol [37, 38].  In addition to the VSV G protein’s tendency to non-
specifically interact with several different lipids, other information has surfaced 
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refuting the hypothesis that phosphatidylserine is the receptor for VSV.  It has been 
shown that there is no correlation between the amount of phosphatidylserine in the 
plasma membrane of a cell and the degree of VSV binding [39].  Also, 
phosphatidylserine is mostly present on the internal leaflet of the cell membrane and 
therefore not readily available to act as a cell surface receptor [40].  Due to the current 
confusion over this topic, further work to identify the receptor for VSV is clearly 
needed. 
 After the receptor binding event, VSV enters the endocytic pathway in a 
clathrin dependent fashion [41-44].  The exact process of fusion and infection, 
however, is less clear.  In 2005, Le Blanc et al proposed a two step mechanisms for 
VSV fusion and infection [45].  Using time-lapse confocal microscopy and a pH 
sensitive dye they determined that fusion must occur at a later stage than the early 
endosome.  Using inhibitors like nocodozole, they determined that fusion must occur 
before VSV reached the late endosome.  This evidence pointed to fusion of the VSV 
virion into the internal vesicles of the endosomal carrier vesicles or multivesicular 
bodies (ECV/MVB).  On top of that, they were able to capture EM images showing 
VSV nucleocapsids inside of the internal vesicles of multivesicular bodies.  Regarding 
VSV infection, they observed that it was disrupted by agents that disrupted late 
endosomes such as nocodozole (in contrast to fusion) and that inhibiting the back 
fusion of the internal vesicles of the MVBs with an anti-LBPA antibody also inhibited 
infection.  In total, they proposed a fusion step of VSV with the internal vesicles of the 
MVBs followed by infection by VSV as a result of back fusion of those vesicles with 
the limiting membrane of the late endosome.  In early 2009, a paper was published 
that proposed an alternative pathway for VSV fusion and infection [42].  Using time-
lapse confocal microscopy and EM they determined that fusion and infection occurred 
in one step in the early endosome by fusion of the endosomal membrane with the viral 
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lipid membrane which resulted in the introduction of the nucleocapsid into the cell 
cytoplasm.  A comparison of the two models can be seen in Figure 1.5.  One key 
difference between these two models is the conditions under which fusion occurs.  In 
the two step model, VSV is fusing to a membrane that contains a specific lipid found 
only in the membrane of the internal vesicles, lysobisphosphatidic acid (LBPA).  In 
chapter 2, I provide evidence that this lipid interacts with the VSV G protein in a 
manner that accelerates fusion, which could contribute to the phenomenon of the two 
step fusion-infection mechanism. 
Figure 1.5 The two proposed VSV endocytic entry pathways. 
 
Coronaviruses 
 The Coronaviridae are large, enveloped positive stranded RNA viruses that 
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can infect humans as well as other domestic birds and mammals [46], Figure 1.6.  The 
family is customarily split into three groups.  Of particular interest here are the group I 
feline coronaviruses, feline enteric coronavirus (FeCoV) and feline infectious 
peritonitis virus (FIPV).  Among group II viruses, severe acute respiratory syndrome 
corona virus (SARS-CoV) a human pathogen, which is actually classified into a 
subgroup of group II, will be a subject of further investigation.  Finally, among group 
III viruses, infectious bronchitis virus (IBV) a significant pathogen of chickens will be 
discussed in comparison with SARS and the feline coronaviruses.  Of particular 
importance to entry and fusion of coronaviruses is the spike (S) glycoprotein which is 
a large, heavily glycosylated protein of approximately 150-180 kDa which is 
embedded into the viral lipid envelope [46].   
Figure 1.6 Schematic representation of coronavirus structure (Stadler, Nat. Micro., 
2003.) 
 
 The coronavirus spike protein is a class I fusion protein [47], however there 
seems to be some variation of certain characteristics such as the necessity for 
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proteolytic cleavage amongst the coronavirus spike proteins.  Although no X-ray 
crystal structure has been obtained of the SARS-CoV S protein, there has been a 
concerted effort to determine aspects of its structure and mechanism of action [48].  
Some structural information has been gleaned from a crystal structure of the receptor 
binding domain complexed to the receptor angiotensin converting enzyme-2 (ACE-2) 
[49].  Further, studies of the heptad repeats have shown that the protein likely exists as 
a monomer in the pre-fusion state and that, upon activation, the heptad repeat domains 
interact in a six-helix bundle and the protein associates into a homotrimer [47, 50].  A 
number of studies of the mechanism of the SARS-CoV S protein have attempted to 
understand the proteolytic processing of the protein.  Studies have shown that the 
spike protein can be cleaved by factor Xa [51], but more importantly, cathepsin L [52, 
53] during entry by the endosomal pathway, and trypsin promoting fusion at the cell 
surface [54-56].  A more recent study shows that a sequential cleavage event is 
necessary to fully activate the SARS-CoV S protein [57].   
 
Figure 1.7 Schematic representation of coronavirus spike protein.  The protein is 
divided into two sections, S1 and S2.  The two heptad repeats are labeled as HR1 and 
HR2 and the transmembrane domain is labeled TM.  The cleavage site internal to S2 is 
labeled S2’. 
 
As mentioned previously, proteolytic cleavage of class I fusion proteins commonly 
exposes the fusion peptide.  There is currently a controversy about the identity of the 
SARS-CoV fusion peptide in the literature.  Several sequences in the protein have 
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been characterized as having the features of a fusion peptide. Initial reports used the 
Wimley and White interfacial hydrophobicity scale to identify two regions including 
amino acids M770-L778 (WW-I) and A864-Y886 as possible fusion peptides.  These 
peptides were shown to induce fusion and leakage of lipid vesicles and possess 
secondary structure alone and in the presence of lipid vesicles [58].  The same group 
has also proposed amino acids 858-886 could be the SARS-CoV fusion peptide in 
analogy to the fusion peptide of the HIV gp41 glycoprotein [59-61].  In chapter 3, I 
will discuss my work characterizing our proposed fusion peptide for SARS-CoV. 
Also presented in chapter 3 is the characterization of the analogous fusion 
peptide for the feline coronaviruses.  The feline coronaviruses are divided into two 
serotypes, type I which account for approximately 80% of all infections [62, 63], and 
type II which are more widely studied in the laboratory due to their ability to be 
propagated in cell culture.  Each serotype can be further divided into two biotypes, 
feline enteric coronavirus (FeCoV) and feline infectious peritonitis virus (FIPV) which 
can only be distinguished biologically [64].  FeCoV is a mild enteric infection which 
in less than 5% of cats, can mutate into the fatal systemic biotype FIPV [65].  
Mutations have been identified in the 3c gene, which encodes for a protein of 
unknown function, that distinguish FIPV from FECV [66].  However, the “internal 
mutation” of FECV into FIPV remains controversial and alternative theories have 
been proposed [67].  It has been well established that type I feline coronavirus spike 
glycoproteins use aminopeptidase N (APN) as their receptor [68].  A recent report 
shows that DC-SIGN can enhance the infection of type II feline coronaviruses in 
permissive cells and rescue it in non-permissive cells [69].  However, the receptor for 
serotype I viruses is currently unknown [70, 71].  A recent report by Regan et. al 
shows that FECV is sensitive to pH as well as cathepsin L and cathepsin B inhibitors 
and FIPV is insensitive to pH and cathepsin L inhibitors but sensitive to cathepsin B 
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inhibitors.  This data could point to different routes of entry for these two viruses, 
FECV utilizing the endosomal pathway and FIPV being able to fuse at the cell surface.  
It also infers that the spike protein of FECV must be cleaved by cathepsins L and B 
while the spike protein of FIPV must only be cleaved by cathepsin B, although further 
work must be done to confirm these hypotheses.  In chapter 3, I will discuss the 
evidence that suggests these two coronaviruses have slightly different fusion peptides 
and the effect that has on their ability to promote membrane fusion. 
 
 
Figure 1.8 Schematic representation of Influenza A virus.  A.  Influenza virion, 
B.  Hemagglutinin (HA) protein (Subbarao & Joseph, Nat. Rev. Immunol., 2007). 
 
 17 
Influenza 
Influenza is an enveloped virus with a negative single-stranded RNA genome, 
as shown in Figure 1.8 [72].  There are 8 segments to the genome which encode 10 or  
11 proteins [73].  Much is known about influenza viruses because they are one of the 
main model systems for host cell-virus interactions.  Of particular interest to studies of 
entry is the influenza glycoprotein hemagglutinin (HA) which is responsible for 
receptor binding and entry.  Influenza hemagglutinin is a class I fusion protein.  
Further discussion of the receptor binding activities of HA can be found in Appendix 
1.  Prior to cleavage, HA is referred to as HA0, the protein is cleaved into two sulfide 
bridged pieces , HA1 which includes the receptor binding domain, and HA2 which is 
responsible for fusion and contains the fusion peptide [4].  To allow for fusion, the 
low pH environment of the endosome is necessary to promote structural 
rearrangement of the HA protein and exposure of the fusion peptide.  Influenza enters 
the cell using multiple endocytic pathways.  Single particle experiments show that 
influenza uses clathrin-mediated endocytosis approximately 60% of the time but also 
uses clathrin and caveolin independent pathways [74].  Studies of the intracellular 
trafficking of influenza virus in polar cells show a significant role of the actin 
cytoskeleton in internalization [75].  In appendix 1, I present my work on defining the 
role of N-linked glycosylation on the entry of influenza virus into human cells.
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CHAPTER 2 
 
PROMOTION OF VIRAL MEMBRANE FUSION BY THE ENDOSOME-
SPECIFIC PHOSPHOLIPID LYSOBISPHOSPHATIDIC ACID (LBPA) 
Abstract 
Vesicular stomatitis virus (VSV) is a prototypic virus that is commonly used in 
studies of endocytosis and membrane trafficking. A proposed mechanism for VSV 
entry involves virus internalization into endosomes, followed by a two-step fusion 
reaction; initial fusion with internal vesicles of multivesicular endosomes followed by 
subsequent back-fusion of these vesicles into the cytoplasm. One feature of the 
internal vesicles of late endosomes is that they uniquely contain the lipid 
lysobisphosphatidic acid (LBPA). Using a FRET-based in vitro lipid mixing assay, we 
show that the presence of LBPA significantly increases the rate of VSV G mediated 
membrane fusion. The increased rate of lipid mixing was selective for VSV and was 
not evident when other viruses, such as influenza, were examined. Our data provide a 
biological rationale for a two-step fusion reaction during VSV entry, and suggests that 
LBPA may preferentially affect the ability of VSV G (a class III viral fusion protein) 
to mediate lipid mixing during membrane fusion. 
Introduction 
The endocytic pathway is responsible for the maintenance of the cell surface 
composition and is usurped by many viruses as a portal of entry into the cell [1]. Such 
viruses often take advantage of the low endosomal pH to trigger their uncoating and/or 
fusion and thus gain access to the cytosol for replication. While low pH is well 
recognized as a way to regulate the conformational changes occurring during virus 
entry, the role of other endosomal factors such as lipid composition remains poorly 
characterized. Vesicular stomatitis virus (VSV) enters cells via clathrin-mediated 
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endocytosis [2, 3], with entry into the cytosol mediated via the viral glycoprotein G 
[4].  VSV G mediates membrane fusion in a low pH-dependent manner, with optimal 
fusion activity at pH 5.7–5.8 or below [3]. VSV G shows unusual properties for a viral 
fusion protein, in that the conformational changes triggering membrane fusion are 
reversible [5]. Another unusual feature of VSV is that viral entry has been proposed to 
be mediated by a two-step fusion reaction, with the initial fusion event occurring with 
internal vesicles of endosomal transport intermediates, followed by a “back-fusion” 
reaction of viral nucleocapsid laden internal vesicles with the limiting membrane of 
late endosomes [6]. This mechanism has been disputed, and a more conventional 
fusion reaction directly with the limiting membrane of early endosomes proposed [2]. 
 Membrane lipids play critical roles in the spatial organization of cells [7] and 
one feature of the internal vesicles of the endocytic pathway is that they contain a 
unique lipid, called either lysobisphosphatidic acid (LBPA) or 
bis(monoacylglycero)phosphate (BMP) [8, 9] LBPA is thought to promote membrane 
fusion and membrane invagination in a low pH-dependent manner [10, 11], and 
control the morphology and function of late endosomes and 4 multivesicular bodies. In 
this manuscript, we considered whether LPBA specifically promotes VSV G-mediated 
membrane fusion, and so provide a rationale for a two-step fusion reaction during 
VSV entry. 
Results and Discussion 
In order to determine the effect of LBPA on VSV G-mediated membrane fusion, we 
adapted a fluorescence resonance energy transfer (FRET)-based assay of lipid mixing 
[12]. In this assay, purified VSV particles are mixed with a liposome population 
consisting of liposomes labeled with both rhodamine-PE and NBD-PE and also 
unlabeled liposomes. A hemifusion or fusion event between a VSV particle and a 
labeled liposome results in a dilution of the FRET pairs and an increase in NBD 
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(donor) fluorescence, which is monitored by fluorescence spectroscopy. We produced 
liposomes that contained LBPA (20% molar ratio), and compared the extent of VSV-
mediated fusion to liposomes without LBPA. A representative experiment is shown in 
Fig 2.1.  
Figure 2.1 Lipid mixing of VSV with liposomes containing 4:5:1 
POPC:POPS:cholesterol or 2:2:5:1 POPC:LBPA:POPS: cholesterol liposomes was 
initiated by a drop in pH, from 7.0 to 5.0. Lipid mixing was followed by monitoring 
fluorescence intensity at 530nm. 4:5:1 POPC:LBPA:POPS:cholesterol liposomes were 
also monitored following the pH drop in the absence of virus particles (-VSV). 
 
Upon addition of VSV particles, both the initial rate of fusion and the extent of fusion 
were increased in the presence of LBPA. In the absence of virus particles, we 
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observed only limited fusion (Figure 2.1).  The rate of VSV-induced lipid mixing 
within the first 10 seconds of the fusion reaction for liposomes with and without 
LBPA, at a range of pH values, is shown in Figure 2.2. At pH values below 6.5, 
liposomes with LBPA had significantly higher rates of lipid mixing than liposomes  
 
Figure 2.2 The rate of lipid mixing during the first 10 seconds of the reaction was 
determined over a range of pH conditions with labeled and unlabeled 4:5:1 
POPC:POPS:cholesterol or 2:2:5:1 POPC:LBPA:POPS:cholesterol liposomes. Each 
data point is averaged from three individual assays and error bars represent standard 
deviation of the mean. 
 
without LBPA. 
The membranes of late endosomes have been reported to contain 
approximately 20% LBPA, which provided us a biologically relevant liposome 
composition to use in our initial experiments. In order to confirm the effect of LBPA 
on VSV G-mediated lipid mixing, we varied the amount of LBPA present in the 
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liposomes and examined the rate of lipid mixing. As shown in Figure 2.3, the rate of 
lipid mixing increases with increasing amounts of LBPA present in the liposome 
composition.  
Figure 2.3 The rate of lipid mixing by VSV G increases with increased LBPA 
The rate of lipid mixing during the first 10 seconds of the reaction, initiated by a 
change to pH 5, was examined with liposomes consisting of a range of LBPA 
quantities (from 0% to 40% of the liposome composition). The kinetics of lipid mixing 
was followed by monitoring NBD-PE fluorescence intensity at 530nm. Each data 
point is averaged from three individual assays and error bars represent standard 
deviation of the mean. 
 To date, a two-step fusion reaction has only been proposed during entry of 
VSV. We therefore examined whether LBPA might promote membrane fusion in 
other viral systems.  We tested the effect of LBPA on membrane fusion mediated by 
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the hemagglutinin (HA) of influenza virus.  As shown in Figure 2.4, our FRET-based 
assay clearly showed that when liposomes were fused with influenza virus (strain  
Figure 2.4 Virus specificity of lipid mixing rate acceleration by LBPA 
A comparison of the rate of lipid mixing for VSV and influenza, both at a 
concentration of 100 μg/ml, with 4:5:1 POPC:POPS:cholesterol or 2:2:5:1 
POPC:LBPA:POPS:cholesterol liposomes at pH 5. Each bar is averaged from three 
individual assays and error bars represent standard deviation of the mean. 
 
X:31), the addition of LBPA had no significant effect on the rate of fusion. 
In contrast, LBPA had a profound effect on the rate of lipid mixing promoted by VSV 
G, suggesting that an interaction with LBPA is specific property of VSV.  
Our data show that the endosome-specific phospholipid LBPA promotes 
membrane fusion mediated by the VSV G protein, and provide a rationale for a two-
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step endosomal fusion reaction during VSV entry. While Gruenberg and colleagues 
considered that LBPA was involved in the back-fusion of VSV G-containing 
endosomal vesicles via the action of Alix [6], a direct role of LBPA in virus-induced 
fusion has not been addressed to date. It has previously been reported that the presence 
of LBPA in liposomes allows spontaneous fusion in a pH-dependent manner [10]. 
While some degree of LBPA-induced liposome fusion in the absence of virus particles 
was observed in our experiments, this was limited compared to fusion promoted by 
VSV G either in the presence or absence of LBPA. Our studies reveal an important 
role for LBPA in directly modulating VSV G mediated membrane fusion.  
It has long been known that the VSV G protein can specifically interact with 
lipids, and a selective interaction with phosphatidylserine was originally proposed to 
account for virus-receptor interactions during entry into the cell [13], although this has 
recently been disputed [14]. In general, VSV G seems to have an affinity for 
negatively charged phospholipids [15, 16]. LBPA is also anionic, and so its charged 
head group could account for the enhancement of VSV G-mediated membrane fusion. 
However, the presence of negative charge does not appear to be the sole way of 
enhancing VSV G-mediated membrane fusion, as other negatively charged lipids such 
as palmitoyl-oleoyl-phosphatidic acid (POPA) showed only minimal enhancement of 
fusion (Figure 2.5).   We assessed the VSV-G mediated fusion of liposomes 
containing other naturally occurring anionic lipids with similar chemical groups to 
LBPA including cardiolipin and POPG, which are commonly called polyglycerolipids.  
The FRET based assay showed that all polyglycerolipids enhanced the rate of VSV-G 
mediated lipid mixing beyond the anionic lipids POPS and POPA.  Although VSV  
would not encounter POPG or cardiolipin during the normal course of host cell 
infection, this experiment shows that the chemical moieties common to this group of 
lipids could be involved in the mechanism of rate enhancement.  Curiously, adding L- 
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Figure 2.5 Effect of anionic lipids on the rate of lipid mixing by VSV-G 
A comparison of the rates of lipid mixing for VSV with 2:2:5:1 
POPC:X:POPS:cholesterol liposomes, where X is the anionic lipid indicated in the 
figure, at pH 5.  Each bar is averaged from three individual assays and error bars 
represent standard deviation of the mean. 
 
α-polyinositol (PI) showed a similar rate of lipid mixing enhancement as the 
polyglycerolipids.  It is possible that the hydroxyl groups on the inositol ring can 
mimic the effect of the glycerol moiety on the polyglycerolipids.  However, more 
experiments determining structure-function relationships would be required to validate 
this hypothesis.  
One notable feature of our experiments is that whereas LBPA promoted VSV 
G-induced membrane fusion, it did not significantly affect influenza HA-mediated 
fusion. The fusion peptides of G and HA are very different; whereas influenza HA has 
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an external α-helical fusion peptide that inserts into the lipid bilayer at an oblique 
angle [17, 18], VSV G has an internal fusion peptide composed of a bipartite loop 
structure that dips into the bilayer [3, 4]. The mechanism by which LBPA induces its 
differential effect of VSV is presently unclear, but it is likely to be related to an 
interaction with the viral fusion peptide. LBPA is a unique derivative of 
phosphatidylglycerol that shows unusual features for a membrane phospholipid [19]. 
One possibility for the effect of LBPA is related to its shape; however whether the 
lipid is cone, inverted cone or cylindrical is shape is unclear [19]. It has previously 
been reported that influenza virus HA-mediated fusion was inhibited by the inverted 
cone-shaped lipid lysophosphatidic acid and promoted by the cone-shaped oleic acid 
[20]. Due to the fact that LBPA showed no effect on influenza virus fusion (Fig 2.4), it 
is unlikely that an equivalent mechanism might underlie the effect of LPBA on VSV 
G—although such a conclusion would need more evidence for the physical behavior 
of LBPA in lipid bilayers.  
There are two known serotypes of VSV, Indiana and New Jersey, which have 
approximately 50% identity in the G protein.  VSV New Jersey is known to fuse at a 
lower pH than the Indiana serotype [21].  Due to this observation, we carried out the 
FRET based assay expecting that VSV New Jersey would show a greater enhancement 
of the lipid mixing rate upon the addition of LBPA because it would encounter more 
LBPA during the normal course of infection (Figure 2.6.)  The result of the assay 
showed the exact opposite result.  As shown in Figure 2.6, the lipid mixing rate for the 
Indiana strain with LBPA was significantly different  (Students’ t test, p≤0.05), 
however, the lipid mixing rates for the New Jersey strain (Students’ t test, p≤0.05), 
however, the lipid mixing rates for the New Jersey strain were not significantly 
different (p≥0.05).  In order to compare the serotypes to each other at the pH values of 
5 and 5.5, due to the quantification of virus by the Bradford assay.   
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Figure 2.6 Comparison of lipid mixing for the two serotypes of VSV 
A comparison of the rates of lipid mixing for VSV Indiana and New jersey 
with 4:5:1 POPC:POPS:cholesterol or 2:2:5:1 POPC:LBPA:POPS:cholesterol 
liposomes at pH 5.  Each bar is averaged from three individual assays and error bars 
represent standard deviation of the mean. 
 
If the ratio of lipid mixing with LBPA to lipid mixing without LBPA is not 
significantly different than one then there is no difference in the rate of lipid mixing.  
As shown in Figure 2.7, at pH 5 the ratio of lipid mixing for VSV Indiana was 
significantly different from 1 (One sample t test, p≤0.05) but the ratio was not 
significantly different for the New Jersey serotype (p≥0.05).  The same trend was also 
evident for Indiana (p≤0.001) and New Jersey (p≥0.05) at pH 5.5.  From this 
experiment it was concluded that one of the amino acids which is different between 
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the two serotypes could be responsible for the interaction with LBPA.  In the fusion 
loops of VSV Indiana and New Jersey there is only a single amino acid difference.  It 
seems unlikely that the change from an alanine residue to a glycine  
Figure 2.7 Comparison of the ratio of VSV-G mediated lipid mixing 
A comparison of the rates of lipid mixing for VSV Indiana and New Jersey with 4:5:1 
POPC:POPS:cholesterol or 2:2:5:1 POPC:LBPA:POPS:cholesterol liposomes at pH 5 
or 5.5.  Each bar was determined from three individual assays of each lipid 
composition and error bars represent propogated error. 
 
residue could be responsible for such a dramatic effect; however an experiment 
examining the effect of mutating A117 to a glycine residue in VSV G Indiana and 
G117 to an alanine in VSV G New Jersey is clearly warranted. 
The role of LBPA and the two-step model of VSV entry remains controversial. 
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It may be that depending on the composition of endosomal domains in different cell 
types, the virus can fuse either directly from the early endosome, or enter via back-
fusion in late endosomes. As indicated in Fig. 2.3, cell types with higher amounts of 
endosomal LBPA may re-direct fusion toward the lumen of the MVB, rather than 
towards the cytosol. Such a variation in the site of fusion during virus entry might be 
facilitated by the relatively broad range of pH values (from approximately 6.2 to 5.0) 
that can activate the VSV G fusion machine. 
VSV G is now considered to be a founder member of the so-called class III of 
viral fusion proteins [18]. Whereas the fusion loops of class III of viral fusion proteins, 
such as VSV G, show some similar features to class II fusion proteins, they retain 
distinctive structural properties [3]. Other class III viral fusion proteins include herpes 
simplex virus glycoprotein B and the baculovirus gp64 [22, 23]; it will be interesting 
to determine whether the promotion of VSV G mediated membrane fusion by LBPA is 
shared with these other viruses. It will also be interesting to address a direct role for 
LBPA in the context of other pathogens that navigate endosomal compartments during 
their entry into host cells [24]. 
Materials and methods 
Viruses and cells 
Vesicular stomatitis virus (VSV) Indiana, strain Orsay (ATCC) was propagated in 
BHK cells (ATCC). Briefly, 80-90% confluent roller bottles of BHK cells were 
infected at a MOI of 0.01. After 24h, the media was spun down and the supernatant 
was subjected to ultracentrifugation. The viral pellet was then applied to a sucrose step 
gradient to produce purified VSV. Viral protein concentration was determined using a 
Bradford protein assay. Influenza A virus, strain X:31 (H3N2), was grown in 11 day 
old embryonated eggs and allantonic fluid was collected to prepare concentrated virus 
stock as described for VSV. 
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Liposomes 
Palmitoyl-oleoyl-phosphocholine (POPC), palmitoyl-oleoyl-phosphoserine (POPS) 
lysobisphosphatidic acid (LBPA), and cholesterol were purchased from Avanti Polar 
Lipids (Alabaster, AL). Labeled phospholipids N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt 
(NBD-PE) and Lissamine™ rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine, triethylammonium salt (Rho-PE) were purchased 
from Invitrogen (Carlsbad, California). Large unilamellar vesicles (LUV) were 
prepared according to the extrusion method. Lipid films were obtained by subjecting 
chloroform dissolved lipid mixtures to high vacuum overnight. Lipid films were 
resuspended by addition of fusion buffer (20 mM MES, 30 mM Tris- 
HCl, pH 7) to 5 or 10 mM lipid concentration and incubated for 15 minutes at room 
temperature followed by vortexing for 15 minutes. Liposomes were then subjected to 
10 freeze-thaw cycles, followed by 11 extrusions through 0.1 μm polycarbonate 
membrane using an Avanti mini extruder. Liposomes labeled with the FRET pairs 
Rho-PE and NBD-PE were made in the same manner with the addition of 0.6% each 
of NBD-PE and Rho-PE to the chloroform-dissolved lipid mixture. 
Lipid Mixing Assay 
Lipid mixing was determined using the method of Struck et al. (Struck et al., 1981). 
Unlabeled and labeled liposomes were mixed at a 4:1 ratio to a total concentration of 
110 μM lipid in fusion buffer at pH 7.0 with continuous stirring. Then VSV was added 
to a final concentration of 200 μg/ml total viral protein unless otherwise noted. To 
initiate fusion, hydrochloric acid was added to the solution until the desired pH was 
achieved. To end the reaction and obtain a measurement of 100% lipid mixing, 
reduced Triton X-100 was added to a final concentration of 0.2%. Changes in 
fluorescence were measured using a QM-6SE spectrofluorimeter (Photon Technology 
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International, Birmingham, NJ) with excitation set at 467 nm and emission monitored 
at 530 and 581 nm. The extent of lipid mixing was determined using the formula: 
 
𝐹𝐹(%) = 𝑓𝑓𝑡𝑡 − 𝑓𝑓0
𝑓𝑓100 − 𝑓𝑓0 × 100 
 
where ft is the fluorescence measurement at time t, f0 is the initial fluorescence and f100 
is the fluorescence after the addition of reduced Triton X-100. All measurements were 
taken in triplicate and averaged. 
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CHAPTER 3 
LIPID MIXING PROMOTED BY NOVEL CORONAVIRUS FUSION PEPTIDES 
Introduction 
 In order to produce progeny a virus must gain entry into a host cell, replicate 
its genetic information and component proteins, and assemble and exit the cell.  In 
order to aid in its entrance into the cell, viruses have developed surface proteins often 
called fusion proteins.  These proteins are able to disrupt the membrane of a host cell 
and facilitate the delivery of the virus’s nuclear material into the cell’s cytoplasm.  The 
part of the fusion protein that actually inserts into the outer leaflet of the cell’s plasma 
membrane is termed the fusion peptide. 
 The fusion peptide has been defined as having several properties [1].  First, a 
fusion peptide must be triggered by environmental conditions to be exposed from a 
protected area within the fusion protein.  It is logical that a fusion peptide would be 
protected during the majority of the virus’s life cycle to prevent non-productive fusion 
events.  Several conditions have been proposed to cause fusion peptide exposure [2] 
including low pH, receptor binding, a combination of low pH and receptor binding and 
proteolytic cleavage.  Secondly, a fusion peptide must insert into the hosts cell’s 
membrane, whether at the cell surface or inside an endosome.  Finally, the fusion 
peptide must be involved in the formation of the fusion pore possibly with other parts 
of the fusion protein such as the transmembrane region.  Although it seems that all of 
these stipulations are self-evident, conclusively proving that a specific peptide has all 
of these properties is a challenging endeavor. 
 Several class I fusion peptides have been identified, and are  listed in Table  
3.1 [3].  Although fusion peptides are not conserved among viruses, several 
characteristics have proven similar among known class I fusion protein fusion 
peptides[4].  Despite the fact that between families, fusion peptides are not conserved, 
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Table  3.1  Amino acid sequences of fusion peptides from Class I fusion proteins.  
Vertical arrows represent protease cleavage sites.  Furin/PC refers to cleavage by a 
protease in the proprotein convertase family. 
 
within a virus family they are one of the most highly conserved protein sequences.  
Usually that sequence is rich in alanines and glycines and can contain several of the 
bulky hydrophobic amino acids.  Overall, the peptide typically has an intermediate 
level of hydrophobicity.  An external fusion peptide is often considered to terminate at 
the first positively charged residue while an internal fusion peptide usually has a 
positively charged residue on the N-terminus and either a positively or negatively 
charged amino acid on the C-terminus.  The total length of an external fusion peptide 
is usually 20-36 amino acids while internal fusion peptides are usually slightly shorter 
16-20 amino acids.  From the amino acid sequence of a fusion peptide, one should be 
able to predict a high potential to bind membranes.  Additionally, it has been found 
that fusion peptides tend to insert themselves into membranes at an oblique angle.  
Due to the fact that a peptide can possess all of these characteristics and still not be a 
viral fusion peptide, experimental evidence must be collected to verify the identity of 
the peptide. 
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Fusion peptide identification and characterization 
 Several techniques have been used to identify fusion peptides in viral fusion 
proteins with various degrees of success.  Even though the characteristics of a fusion 
peptide listed previously can help identify the peptide, the peptide must still be shown 
to be exposed by an environmental trigger, insert into the host cell’s membrane, and 
promote formation of the fusion pore as previously described.  Whereas a single 
experiment cannot prove a peptide is able to perform all of these tasks, usually several 
experiments can provide enough information to determine the identity of a fusion 
protein’s fusion peptide. One of the most helpful tools used in identifying fusion 
peptides is X-ray crystallography.  By obtaining a crystal structure of a fusion protein 
in its pre- and post-fusion forms, the fusion peptide can usually be identified.  Crystal 
structures proved to be of great assistance in determining the identity of the fusion 
peptide of the influenza HA protein[5], and more recently, the fusion loops of the 
vesicular stomatitis virus G protein[6, 7].   Unfortunately, fusion protein crystal 
structures cannot be used alone to determine the identity of the fusion peptides.  Often 
times, it is extremely difficult to crystallize a virus fusion protein due to their usually 
extensive glycosylation patterns and the difficulty of obtaining enough protein to even 
attempt to grow a crystal.  Additionally, a crystal structure cannot prove that a peptide 
is inserted into a membrane or that it forms the fusion pore.  Fortuitously, other 
methods are available that can answer those questions.  Another widely used method 
to identify a fusion peptide is sequence and mutational analysis.  Although the fact that 
a protein sequence is highly conserved among a virus family does not prove it is the 
fusion peptide, it can strengthen the argument when taken into consideration with 
other experimental data [2].  Mutational analysis commonly consists of replacing the 
residues of the fusion peptide, usually with alanine, and determining the effect on 
fusion.  When critical residues of the fusion peptide are significantly changed, fusion 
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is usually decreased as determined by cell-cell fusion assay,  pseudoviral or 
recombinant virus infection assay.  The identification of residues that have a large 
influence on fusion does not guarantee that they are located in the fusion peptide, but 
it is a common way to corroborate evidence from subsequent experiments.  The use of 
spectroscopic techniques such as circular dichroism (CD) and Fourier transform 
infrared spectroscopy (FTIR) have also been used to probe fusion peptides.  Many 
fusion peptides have high degrees of alpha helical character that can be identified by 
these methods.  Additionally, a variation of FTIR using attenuated total reflectance 
(ATR-FTIR) can be used to determine the angle of insertion of a peptide into a 
membrane bilayer.  Characteristically, fusion peptides insert into lipid bilayers at an 
oblique angle[8] from approximately 20-60⁰ in other words, at an angle more parallel 
to the bilayer than perpendicular.  However, again, these spectroscopic methods 
cannot determine the fusion peptide of a fusion protein since they only characterize its 
structure.  There have been several literature reports of using photolabeling and cross 
linking to a membrane to identify a fusion peptide.  This method, though technically 
challenging, can be used to establish that the sequence in question is environmentally 
triggered and inserts itself into membranes.  Although the results can be difficult to 
interpret at times[9], it has been useful in identifying  fusion peptides from several 
viruses[10].  Finally, various assays with liposomes have been used to probe the 
mechanism of fusion by viruses, fusion proteins, and fusion peptides[11].  This assay, 
when carried out with a synthetic peptide of the proposed fusion peptide, can provide 
support that the peptide can insert into membranes and cause lipid mixing and/or 
fusion pore formation. 
Liposome based fusion assays 
 Assays with liposomes and fusion peptides can be used to determine whether 
the fusion peptide being examined has the ability to insert into the lipid bilayer and 
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promote lipid mixing.  Steps which must be accomplished in order to advance towards 
the formation of the fusion pore.  In vitro liposome experiments require the use of a 
synthetic peptide to approximate the behavior of the viral fusion protein.  Although 
one can imagine that the conformation and behavior of a peptide in the context of a 
protein could be vastly different than as an isolated peptide, experiments have shown 
that these peptides are sensitive to mutations and environmental factors (such as pH) 
as predicted by experiments with the entire fusion protein or virus[12].  There are two 
main types of fusion assays involving liposomes that can be used to assess the fusion 
abilities of a peptide, as shown in Figure 3.1 [13].  
 
Figure 3.1 Lipid mixing/fusion assays involving liposomes.  A.  Terbium-dipicolinic 
acid (DPA) content mixing assay.  B. FRET based dye dilution lipid mixing assay. 
 
The first is content mixing assays which involve the inclusion of a reporter molecule 
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in the liposomes.  When peptide induced leakage of the liposome contents occurs, the 
fluorescence of the reporter molecule changes indicating a perturbation of the lipid 
bilayer.  Commonly, the interaction between terbium (Tb) and dipicolinic acid (DPA) 
or aminonaphtalene trisulfonic acid (ANTS) and bis(pyridinium) bromide (DPX) are 
used [13].  The second type of fusion assay involving liposomes, which was used to 
explore the activities of coronavirus fusion peptides in this report, is referred to as dye 
dilution assays.  The most commonly used assay of this type was developed by Struck 
et. al[14]  and has been used to examine the properties of several fusion peptides to 
date[12].  The most frequently used dyes for a dye dilution assay are 7-nitrobenz-2-
oxa-1,3-diazol-4-yl (NBD) and rhodamine (Rh) which can be tethered to a lipid such 
as phosphatidylethanolamine (PE) or cholesterol, but other appropriate FRET pairs 
can also be utilized[15].  The energy transfer is a non-radiative process dependent on 
the extent of overlap of the emission spectrum of the donor with the absorption 
spectrum of the acceptor, orientation of the dye molecules, and distance[16].  This 
assay takes advantage of the effect of distance on the fluorescence of the donor and 
acceptor.   In the assay, two populations of liposomes are present, one labeled with 
both NBD-PE and rhodamine-PE and one without either dye.  When the fusion 
peptide is added and the pH lowered, the fusion peptide induces aggregation and 
fusion.  When a labeled liposome fuses with an unlabeled liposome, dye dilution takes 
place, increasing the distance between the FRET pairs and decreasing energy transfer.  
The result is a measureable increase in the fluorescence intensity of the donor dye and 
a decrease in the intensity of the acceptor dye.  To determine full fusion, at the 
conclusion of the reaction, reduced Triton-X100 is added to the reaction.  The total 
extent of fusion promoted by the peptide can then be calculated with the following 
formula[17]: 
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𝐹𝐹𝑡𝑡(%) = [(𝐼𝐼𝑡𝑡 − 𝐼𝐼0)/(𝐼𝐼𝑡𝑡 − 𝐼𝐼0)]𝑥𝑥100 
 
The dye dilution assay is generally more sensitive than content mixing assays, and 
require less fluorescent probe.  The procedure involved in carrying out the lipid 
mixing assay using the dye dilution method will be discussed in detail in the materials 
and methods section below.  The liposome FRET assay has been used to probe the 
fusion peptides of a variety of viruses including influenza [18, 19], HIV [20, 21], 
Sendai virus [22], Ebola [23, 24] and severe acute respiratory syndrome-associated 
coronavirus (SARS) [25, 26]. 
Coronaviruses 
 Coronaviruses are large, enveloped, positive-stranded RNA viruses known to 
cause disease in birds and mammals, including humans [27].  Of special interested to 
this report are infectious bronchitis virus (IBV), feline infectious peritonitis virus 
(FIPV), feline enteric coronavirus (FECV) and severe acute respiratory syndrome 
virus (SARS).  Although these viruses belong to different coronavirus antigenic 
groups, and infect different species, they show structural similarities among their spike 
proteins.  The coronavirus spike protein is generally said to contain two domains.  The 
S1 domain contains the receptor binding site which is significantly different among 
these viruses.  For example, it is known that FIPV uses feline aminopeptidase  N 
(APN) as a cellular receptor, while SARS is known to use angiotensin-converting 
enzyme 2 (ACE2) [28].  Additionally, it has been recently shown that both of these 
viruses can also use C-type lectins to enhance attachment to cells [29, 30].  The S2 
domain is thought to be responsible for fusion with the host cell membrane.  
Currently, the identity of the fusion peptide in all of these viruses is unknown.  There 
have been several reports in the literature of segments of the SARS S protein that has 
an influence on fusion [25, 26, 31, 32] and could be the fusion peptide.  The authors of 
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these papers suggest three sections or peptides within the SARS S protein that 
potentially have a role in fusion.  They were identified using the Wimley and White 
hydrophobicity interface scale which rated these S protein regions as being highly 
likely to associate with lipid membranes.  The first region, termed WWI is N-terminal 
to our proposed fusion peptide and consists of residues 770-788.  The second region 
WWII is C-terminal to our proposed fusion peptide and consists of residues 864-886.  
Both of these fusion peptides are N-terminal to the two heptad repeat regions.  More 
recently the authors proposed a third region near the transmembrane region which they 
named SARSPTM which they identify as consisting of residues 1187-1200.  The 
authors carry out numerous biochemical assays with synthetic peptides including 
peptide-lipid membrane binding assays, liposome based lipid mixing and content 
leakage assays, circular dichroism spectroscopy and others in order to show that the 
proposed fusion peptides can bind and penetrate membranes and promote fusion.  
Additionally, they show that these regions have other properties, such as structure, 
which are similar to known fusion peptides.  A second group has mutated the region 
identified as WWI and shown that mutations in this region can reduce fusion in cell-
cell fusion assays as much as 70%.  Despite their efforts, the data presented in the 
literature thus far supporting these three fusion peptides is inconclusive.   
Previous work in the Whittaker lab has revealed that the coronavirus IBV Beaudette 
strain contains a furin cleavage site between residues 687 and 690, named S2’[33].  
Upon exposure of the IBV Beaudette spike protein to furin, a cleavage product can 
clearly be observed.  Alignment of IBV Beaudette with other coronaviruses shows that 
an arginine residue, which is a potential protease cleavage site, and the sequence C-
terminal to the cleavage site is highly conserved among coronaviruses, Figure 3.2.   
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Figure 3.2 Alignment of coronavirus spike proteins.  The graph shows the degree of 
homology in the spike protein of the coronavirus family.  Shown below are the 
sequences of the proposed fusion peptides in the three classes of coronaviruses. 
(Madu, Roth, et. al, J. Virol., 2009). 
 
These observations lead to the examination of this cleavage site in SARS and the 
prediction that cleavage at this location exposed the fusion peptide.  It has been 
determined that mutations at the S2’ cleavage site in SARS inhibits fusion.  
Additionally, replacing the two basic residues K796 and R797 with a furin cleavage 
site enhances cleavage and fusion[33].  Subsequently, it has been shown that mutation 
to the region succeeding the cleavage site has a deleterious effect on fusion in cell-cell 
fusion assay and infection when the mutations are incorporated into pseudoviral 
particles [34].  
 Closer examination of the coronaviruses shows that one member of the family, 
FIPV, contains a mutation at the otherwise conserved protease cleavage site, as shown 
in Table 3.2. 
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Table 3.2 Sequence alignment of coronavirus S2’ cleavage sites.  Vertical bars 
represent potential protease cleavage sites. 
 
Due to the fact that FIPV has a glycine instead of arginine residue at the S2’ site, it is 
reasonable to assume that the cleavage site that exposes the fusion peptide could have 
shifted in this case.   After analyzing the cleavage site preference of cathepsin L and B 
which are known to cleave the feline coronavirus S proteins, we determined that it is 
possible that the FIPV spike protein could be cleaved one or two residues N-terminal 
to the fusion peptide, as indicated in Figure 3.3 by the vertical lines.  Addition of one 
or two residues to the N-terminus of the FIPV fusion peptide could have a profound 
effect on its ability to mediate lipid mixing. 
Based on all of these observations we decided to investigate the synthetic 
fusion peptides of the coronaviruses IBV, SARS, FIPV and FECV to determine 
whether these peptides are capable of associating with membranes and promoting lipid 
mixing.  Although these experiments do not prove that these sequences are indeed the 
fusion peptides of these viruses, they lend support to the hypothesis that these regions 
are capable of insertion into the host cell membrane and that they could be responsible 
for the formation of the fusion pore. 
 
Materials and Methods 
Peptides 
The coronavirus fusion peptides, Table 1, were synthesized using solid phase 
techniques by New England Peptide (Gardner, MA).  
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Table 3.3 Synthesized coronavirus fusion peptide sequences. 
Coronavirus Fusion Peptide Sequence 
IBV  SLIEDLLFTSVESGCGKKK 
SARS SFIEDLLFNKVTLADAGFMKQYGCGKKKK 
SARS short SFIEDLLFGCGKKKK 
SARS LLF-AAA SFIEDAAAGCGKKK 
FIPV YGSAIEDLLFDKVVTSGLGGGCGKKKK 
FIPV-Y GSAIEDLLFDKVVTSGLGGGCGKKKK 
FECV SAIEDLLFDKVVTSGLGGGCGKKKK 
Negative Control GCGKKKK 
 
The GCGKKKK linker was included to promote liposome association as described for 
the host-guest fusion peptide system of Han and Tamm [18]. Purity as determined by 
HPLC was greater than 95%, and mass identification was performed by MALDI-TOF 
mass spectrometry.  Peptides were resuspended to 5 mg/ml in sterile MilliQ water. 
Control peptides were treated identically and had the sequence SIRYSFCGNGRHV 
for circular dichroism spectroscopy experiments and GCGKKKK for lipid mixing 
experiments.  
Liposomes 
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine (POPC), 1-Palmitoyl-2-Oleoyl-
sn-Glycero-3-[Phospho-L-Serine] (Sodium Salt) (POPS), 1-Palmitoyl-2-Oleoyl-sn-
Glycero-3-[Phospho-rac-(1-glycerol)] (Sodium Salt) (POPG), and cholesterol were 
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purchased from Avanti Polar Lipids (Alabaster, AL). Labeled phospholipids N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine, triethylammonium salt (NBD-PE) and Lissamine™ rhodamine 
B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt 
(Rho-PE) were purchased from Invitrogen (Carlsbad, California). Large unilamellar 
vesicles (LUV) were prepared according to the extrusion method. Lipid films were 
obtained by subjecting chloroform dissolved lipid mixtures of 1:3:1 
POPC:POPS:cholesterol in the case of IBV, SARS and SARS short, and 4:1 
POPG:cholesterol in the case of FIPV, FIPV-Y, and FECV, to high vacuum overnight. 
Lipid films were resuspended by addition of fusion buffer (5 mM HEPES, 5 mM 
MES, 5mM sodium succinate, 150 mM sodium chloride, pH 7) to 5 or 10 mM lipid 
concentration and incubated for 15 minutes at room temperature followed by 
vortexing for 15 minutes. Liposomes were then subjected to 10 freeze-thaw cycles, 
followed by 11 cycles of extrusion through 0.1 µm polycarbonate membrane using an 
Avanti mini extruder. Liposomes labeled with the FRET pairs Rho-PE and NBD-PE 
were made in the same manner with the addition of 0.6% each of NBD-PE and Rho-
PE to the chloroform-dissolved lipid mixture. 
Lipid Mixing Assay 
Lipid mixing was determined using the method of Struck et al. [14]. Unlabeled and 
labeled liposomes were mixed at a 4:1 ratio to a total concentration of 110 µM lipid in 
fusion buffer at pH 7.0. Hydrochloric acid was added to the solution until the desired 
pH was achieved. To initiate fusion, peptide was added to the specified concentration. 
To end the reaction and obtain a measurement of 100% lipid mixing, reduced Triton 
X-100 was added to a final concentration of 0.2%. Changes in fluorescence were 
measured using a QM-6SE spectrofluorimeter (Photon Technology International, 
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Birmingham, NJ) with excitation set at 467 nm and emission monitored at 530 and 
581 nm. The extent of lipid mixing was determined using the previously discussed 
formula.  All measurements were taken in triplicate and averaged. 
 
Results 
IBV 
In order to determine the capability of the proposed coronavirus fusion peptide 
to promote lipid mixing, the IBV fusion peptide shown in Table 3.1 was subjected to 
the described lipid mixing assay.  The extent of lipid mixing was monitored as an 
increase in NBD fluorescence over three trials and the averages at different peptide 
concentrations is represented in Figure 3.3.  The IBV fusion peptide was able to 
promote a high amount of lipid mixing at pH 5, and was almost completely unable to 
promote lipid mixing at pH 7.     
 
SARS 
To determine whether the ability of the proposed fusion peptide to promote lipid 
mixing was characteristic of this sequence in the other members of the coronaviradea 
family, we examined the SARS fusion peptide under similar conditions to that of the 
IBV fusion peptide.  The extent of lipid mixing promoted by the SARS fusion peptide 
and monitored in the FRET-dilution assay are shown in Figure 3.4.  From these 
experiments it is evident that the SARS fusion peptide is able to mediate lipid mixing 
at both pH 5 and 7, unlike the IBV peptide which is only able to mediate lipid mixing 
at pH 5.  Although it is possible for the SARS fusion peptide to mediate lipid mixing 
in both pH conditions, the SARS fusion peptide is able to promote a higher extent of 
lipid mixing at lower peptide concentrations at pH 5.  It should be noted that the 
negative control peptide GCGKKK, which increases the solubility of the fusion 
peptide, was included in these lipid mixing experiments to show that this region does  
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Figure 3.3 The IBV S2 fusion peptide induces lipid mixing in liposomes Extent of 
lipid mixing was determined by varying the ratios of IBV S2 fusion peptide with total 
concentration of labeled and unlabeled 1:3:1 POPC:POPS:cholesterol liposomes at pH 
5 and pH 7. The kinetics of mixing was followed by monitoring fluorescence intensity 
at 530nm upon addition of peptide.   
 
not promote lipid mixing independent of the fusion peptide.  
To further examine the pH dependence of the SARS fusion peptide, we 
determined its ability to mediate lipid mixing at pH values in between pH 5 and 7.  It  
can be seen in Figure 3.5 that lipid mixing mediated by the SARS fusion peptide has 
an almost linear dependence on pH. 
 
 
 57 
 
 
 
Figure 3.4 The SARS-CoV S2 fusion peptide induces lipid mixing in liposomes. 
Extent of lipid mixing was determined by varying the ratios of SARS-CoV S2 fusion 
peptide or control peptide concentrations with total concentration of labeled and 
unlabeled 1:3:1 POPC:POPS:cholesterol liposomes at pH 5 and pH 7. The kinetics of 
mixing was followed by monitoring fluorescence intensity at 530nm upon addition of 
peptide. Each data point is averaged from three individual assays and error bars 
represent standard deviation of the mean. 
 
. 
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Figure 3.5 Effect of pH on SARS-CoV S2 fusion peptide mediated lipid mixing. The 
kinetics of lipid mixing was followed by monitoring NBD-PE fluorescence intensity at 
530nm in varying pH environments (from pH 7.0 to pH 5.0). Each data point is 
averaged from three individual assays and error bars represent standard deviation of 
the mean. 
 
A significant experiment which can lend support to the identification of a 
fusion peptide is to show that mutations that abolish fusion in the cell based assays 
also prevent lipid mixing in liposome based assays with the isolated, synthetic peptide.  
Figures 3.6 and 3.7 show the effect of mutating key residues in the SARS fusion 
peptide,  LLF, which were identified in cell-cell fusion and pseudovirus assays [34].  
Mutation of these residues to alanine completely destroys the ability of the peptide to 
promote lipid mixing at both pH 5 and 7.   
 59 
Figure 3.6 Lipid mixing by a short SARS-CoV S2 fusion peptide and a modified 
fusion peptide.  The SARS short fusion peptide was able to mediate fusion at pH 7.  
Mutation of the core residues identified by cell-based assays, LLF, to AAA destroyed 
the ability of the peptide to mediate lipid mixing at pH 7. 
 
Feline Coronaviruses (FCoVs) 
To advance our theory about the identity of the coronavirus fusion peptide, we 
also examined the hypothesized feline coronavirus fusion peptides.  The FECV spike 
protein contains an analogous S2’ cleavage site and fusion peptide as was discussed in 
Figure3.3 and 3.4 and the exact sequence of the synthetic peptide is shown in Table 
3.1.  However, FIPV has a mutation in its spike protein at the S2’ position which 
could shift the cleavage site as depicted in figure 3.3 and discussed previously.  In 
order to address this issue we characterized two peptides to represent the potential 
fusion peptide of FIPV, one with a tyrosine and glycine residue at the N-terminus and 
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Figure 3.7 Lipid mixing by a short SARS-CoV S2 fusion peptide and a modified 
fusion peptide.  The SARS short fusion peptide was able to mediate fusion at pH 5.  
Mutation of the core residues identified by cell-based assays, LLF, to AAA destroyed 
the ability of the peptide to mediate lipid mixing at pH 5.  
 
a separate peptide with a glycine residue at the N-terminus.  We carried out lipid 
mixing experiments on all of these possible feline coronavirus fusion peptides to better 
understand the effect of the N-terminal residues.  The lipid mixing experiments were 
performed under similar conditions as the IBV and SARS experiments except that the 
composition of the liposomes was 4:1 POPG: cholesterol instead of 1:3:1 
POPC:POPS:cholesterol.  This change in liposome composition was necessary 
because the FECV peptide did not mediate lipid mixing with the composition used in 
the SARS and IBV experiments.  Figure 3.8 shows the extent of lipid mixing, as 
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monitored by an increase in NBD fluorescence in the FRET-based lipid mixing assay, 
of the three feline coronavirus fusion peptides at pH 5.  The fusion peptide of FIPV 
was able to mediate a higher extent of lipid mixing at a lower concentration of peptide 
than the FIPV-Y and FECV peptides.  The ability of the FIPV-Y and FECV fusion 
peptides to promote lipid mixing at pH 5 is almost identical.   
. 
Figure 3.8 The FCoV S2 fusion peptides induce lipid mixing in liposomes at pH 5. 
Extent of lipid mixing was determined by varying the ratios of FCoV S2 fusion 
peptides with total concentration of labeled and unlabeled 4:1 POPG:cholesterol 
liposomes at pH 5. The kinetics of mixing was followed by monitoring fluorescence 
intensity at 530nm upon addition of peptide. Each data point is averaged from three 
individual assays and error bars represent standard deviation of the mean.   
 
We also examined the behavior of the feline coronaviruses at pH 7 as shown in 
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Figure 3.9.   The FIPV fusion peptide is still able to promote lipid mixing, although at 
a higher concentration of peptide than was required at pH 5.  The FIPV-Y peptide is 
also able to minimally promote lipid mixing at extremely high concentrations of 
peptide.   
 
Figure 3.9 The FCoV S2 fusion peptides induce lipid mixing in liposomes at pH 7. 
Extent of lipid mixing was determined by varying the ratios of FCoV S2 fusion 
peptides with total concentration of labeled and unlabeled 4:1 POPG:cholesterol 
liposomes at pH 7. The kinetics of mixing was followed by monitoring fluorescence 
intensity at 530nm upon addition of peptide.  
Finally, the FECV fusion peptide is unable to promote lipid mixing even at the 
highest concentrations of peptide.   
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Discussion 
 The fusion protein of a virus and its fusion active component, the fusion 
peptide, are of central importance in the life cycle of a virus.  Although much has been 
learned about fusion proteins and peptides for several viruses, including influenza, 
much about them is still a mystery.  Here, we have shown evidence that a peptide in 
the S2 region in coronavirus fusion proteins, which is C-terminal to a cleavage site, 
has the potential to be the coronavirus fusion peptide.   
  Our experiments with the IBV fusion peptide in the FRET-based lipid 
mixing assay showed that the ability of the peptide to promote lipid mixing was 
dependent on pH.  IBV is known to be a pH dependent virus [35], and probably enters 
cells through the endosomal pathway.  The fact that the fusion peptide is active at low 
pH and inactive at neutral pH could contribute to the pH dependence of the virus.  It is 
possible that the IBV fusion peptide adopts the correct structure to promote lipid 
mixing at low pH and cannot obtain that structure at neutral pH.  When comparing the 
IBV peptide to the SARS peptides it is not obvious why the behavior of these two 
peptides is so different at pH 7.  Although it is reasonable to think that the overall 
charge of the IBV, SARS and SARS short peptides could explain the pH dependence, 
closer examination of that hypothesis reveals deeper complexity.  The IBV synthetic 
peptide contains 3 charged residues (excluding the linker region) and is closest in 
length to SARS short.  SARS short contains 2 charged residues (excluding linker) and 
displays a similar ability to promote lipid mixing at pH 5 and 7.  From this comparison 
one might assume that a decrease in charged residues leads to a decrease in pH 
dependence of lipid mixing.  However, the longer synthetic version of the SARS 
fusion peptide has 5 charged residues (excluding linker), two more than the IBV 
synthetic peptide, and is able to promote fusion at pH 7, disproving the previous 
hypothesis.    To completely rule out the effect of charge, an IBV and SARS synthetic 
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peptide of the same length would have to be subjected to the lipid mixing assay.  
Another possible explanation could be the influence of the charged residues on the 
fusion peptide secondary structure.  The exact position of the charged residues within 
the IBV and SARS fusion peptides are different.  It is possible that those charged 
residues are affecting the structure of those peptides differently as a function of 
position and pH. To further explore this hypothesis, structural studies of several 
modified fusion peptides which compare mutations at these charged residues at pH 5 
and 7 would be required.  Overall, the fact that the ability of the IBV fusion peptide to 
promote lipid mixing is pH dependent confirms that it acts as expected in different 
environments, lending strength to the argument that this region is the fusion peptide 
for IBV. 
 Experiments characterizing the ability of our proposed SARS fusion peptide to 
promote lipid mixing showed that it is able to do so at pH 5 and 7.  This result is 
reasonable considering that SARS can infect cells by fusion at the cell membrane or in 
the endocytic pathway [36].  Additionally, comparison of lipid mixing experiments 
with the short SARS peptide and the long SARS peptide, show that the short peptide is 
less sensitive to pH than the long version of the SARS fusion peptide.  From these 
observations it is possible to hypothesize that the residues SFIEDLLF are responsible 
for the lipid mixing activity.  The residues NKVTLADAGFMKQY, which are present 
in the long peptide but not the short version,  seem to have a pH dependent influence 
on lipid mixing which can be explained by the presence of charged residues in that 
portion of the peptide.  Further experiments showed that mutation of the core residues 
of the synthetic SARS fusion peptide, LLF, to alanine destroyed the peptide’s ability 
to mediate lipid mixing.  This result is similar to that seen in the cell based assays, and 
highlights the close agreement between the in vitro assay and the function of the 
fusion peptide in the context of the virus. 
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  Experiments with the proposed feline coronavirus fusion peptides showed that 
the position of the S2’ cleavage site and therefore the sequence of the fusion peptide 
had a drastic effect on the peptide’s ability to mediate lipid mixing.  The fusion 
peptide for FIPV was able to promote lipid mixing at both pH 5 and 7.  The proposed 
fusion peptide for FECV was able to promote lipid mixing at pH 5 but completely 
unable to aid in lipid mixing at pH 7.  The intermediate peptide, called FIPV-Y, which 
had an N-terminal glycine residue was able to promote lipid mixing at pH 5 to a 
similar extent as the FECV fusion peptide but was only able to promote lipid mixing 
at pH 7 when a large concentration of fusion peptide was used. These results indicate 
that the N-terminal tyrosine and glycine of the FIPV fusion peptide have a pH 
dependent effect on lipid mixing.  At pH 5, the tyrosine residue increases the extent of 
lipid mixing, but at pH 7 the tyrosine and glycine residues cooperatively increase the 
ability of the fusion peptide to promote lipid mixing.  Without these crucial residues, 
the fusion peptide is unable to promote lipid mixing at pH 7.  It is known that FECV is 
pH dependent, while FIPV is not [37], and the behavior of the fusion peptide could 
contribute to the difference in pH dependence and even the difference in pathogenicity 
of the two viruses.  More explicitly, if the mutation in S2’ cleavage site leads to the 
addition of a tyrosine and glycine residue to the N-terminal end of the fusion peptide, 
FIPV would be able to fuse with cells at neutral pH at the cell surface.  This could 
allow FIPV to expand its cell tropism to monocytes because it can now avoid the harsh 
environment of the monocyte endosomal pathway.  Therefore, FIPV can infect a 
larger range of cell types and, as a consequence, is a more widely spread and lethal 
virus.   
Conclusions 
 The mechanism of fusion is relevant in many critical processes effecting 
human life from the release of neurotransmitters to the entry of viruses into cells.  In 
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our efforts to understand this process, viral fusion proteins have been identified as a 
key component of viral entry and a model to help us understand membrane fusion.  
Despite the fact that much has been learned, there is still more to be discovered.  It is 
hoped that by identifying the fusion peptide, the part of the viral fusion protein that is 
inserted into the host membrane, we might be able to stop or restrict this process, 
leading to a new therapeutic strategy.   
 A significant amount of experimental evidence has been revealed suggesting 
that the region C-terminal to the S2’ cleavage site is the fusion peptide in many if not 
all of the members of the coronavirus family.  Here, we provided evidence showing 
that this region is able to associate with lipid membranes and mediate lipid mixing as 
would be expected of a fusion peptide.  Additionally, many of these peptides did so in 
a way that parallels the pH dependence of the virus in question.  This hypothesized 
fusion peptide possesses several characteristics that make it a better candidate than the 
previously suggested regions of the S protein.  Most important is the fact that our 
hypothesized fusion peptide is highly conserved among the coronaviruses, unlike 
WWI and WWII.  Also, our fusion peptide is N-terminal to an established protease 
cleavage site, and the previously suggested fusion peptides are not.  Granting that 
these experiments do not prove this region is the fusion peptides, more work must be 
done.  Ideally, an experiment proving that this region is actually inserted into the host 
membrane during infection and that it causes the formation of the fusion pore is 
needed.  It is possible that this could be accomplished through the use of a fusion 
peptide antibody.  If an antibody to the coronavirus fusion peptide was shown to have 
a deleterious effect on infection, it could be used to show that the fusion peptide is 
exposed after an environmental trigger and that it is inserted into the host cell 
membrane.  Perhaps antibody experiments as described in combination with all of the 
other evidence gathered thus far would be enough to prove the region N-terminal to 
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the S2’ cleavage site is the fusion peptide.   Alternatively, membrane cross-linking 
experiments could be used to show that the region in question is inserted into the 
membrane after being triggered by environmental conditions.  A membrane cross-
linking experiment would also be very persuasive in building a case for the identity of 
the coronavirus fusion peptide.  Due to the controversy surrounding the identification 
of the coronavirus fusion peptides, as well as the need to understand these potentially 
devastating human pathogens, it is certain that experiments that conclusively identify 
the fusion peptide are actively being sought out. 
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CHAPTER 4 
SUMMARY AND CONCLUSIONS 
 Viral entry is an extremely active and important area of research.  By 
investigating the first interactions of viruses with their host cells not only do we learn 
possible ways to prevent infection, but we also learn about natural cell processes.  The 
studies outlined in this thesis contribute to our understanding of the entry mechanism 
of VSV, the fusion mechanism of coronaviruses. 
Summary and Conclusions 
 Vesicular stomatitis virus has been used as a model of virus-host cell 
interactions for an extended period of time.  Although VSV is well studied, there are 
details of its entry mechanism which are still unknown.  In chapter 2, we investigated 
the interaction of the glycoprotein of VSV with the endosome specific lipid LBPA.  
We found that the VSV G protein interacted with LBPA in a manner that accelerated 
fusion.  Additionally, this interaction was specific to VSV G and the presence of 
LBPA did not accelerate the fusion rate of other viruses.  These observations provide 
an explanation for a two-step fusion and infection mechanism where VSV fuses into 
the internal vesicles of MVBs followed by infection from the late endosome.  Due to 
the fact that LBPA is present in the internal vesicles of the MVBs our evidence 
supports the hypothesis by showing that the VSV G protein interacts with LBPA 
which encourages fusion with these vesicles.  The two step entry mechanism proposed 
for VSV and supported by our experiments is unique and, with further study, could 
provide insight into the regulation of the endosomal pathway. 
 The merging of the viral envelope with the host cell membrane is mediated by 
the viral fusion protein.  Specifically, the fusion peptide is inserted into the host cell 
membrane and functions to destabilize the host cell  membrane and bring the viral and 
host cell membrane close enough together to promote fusion.  In chapter 3, we 
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characterize the ability to promote lipid mixing of our proposed coronavirus fusion 
peptides.  We show that the proposed fusion peptides have the ability to promote lipid 
mixing and therefore could be inserted into the host cell membrane and cause the 
formation of the fusion pore.  Additionally, we see evidence in our lipid mixing assay 
that some of the fusion peptides promote lipid mixing in a pH dependent manner 
which is analogous to the pH requirements of the virus.  These correlations suggest 
that the ability of the fusion peptide to promote lipid mixing could contribute to the pH 
dependence of this family of viruses.  Additionally, we observed that mutations to the 
important residues of our fusion peptides abolished its ability to promote lipid mixing.   
Indicating that small changes in our fusion peptide can have a devastating effect on its 
activity which correlates with cell based assays.   
Future Directions 
 Identification of an interaction between the VSV G protein and the lipid LBPA 
is just the first step towards supporting the two step mechanism of VSV entry.  Future 
experiments could include extensive mutagenesis of the VSV protein in an attempt to 
determine which residues are responsible for this effect.  Additionally, it would be 
interesting to attempt to manipulate the conditions of cells and determine the effect of 
different stressors on the entry pathway taken by VSV.  It might be possible to find an 
environmental factor that made one pathway or the other more favorable.  These lines 
or research would help us further understand this novel entry pathway. 
 A significant amount of experimental evidence has been revealed suggesting 
that the region C-terminal to the S2’ cleavage site is the fusion peptide of the 
coronavirus family.  However, we have still not conclusively proven that this region is 
the fusion peptide.  As stipulated previously, an experiment must be carried out 
showing that cleavage at S2’ exposes our proposed fusion peptide.  One possible way 
to do that would be to make an antibody to the coronavirus fusion peptide.  Using this 
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antibody it would be possible to establish whether the fusion peptide was exposed 
upon cleavage.  Additionally, if it could be shown that the antibody blocks infection, 
this evidence could indicate that the antibody is preventing the insertion of the fusion 
peptide into the host cell membrane.  In addition, it is necessary to show that the 
proposed fusion peptide promotes the formation f the fusion pore.  In order to prove 
this, a membrane cross linking experiment could be employed to show that our 
proposed fusion peptide is specifically being inserted into the host cell membrane.  As 
a direct result of the high level of interest in coronaviruses and their potential has 
significant human pathogens as proven by the SARS outbreak of 2003, I believe that 
all of these methods will be utilized to further our understanding of the coronavirus 
fusion machinery. 
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APPENDIX 1 
 THE EFFECT OF N-GLYCOSYLATION OF HUMAN CELLS ON INFLUENZA 
INFECTION 
 
 Introduction 
Influenza 
 Influenza is an enveloped virus with a negative single-stranded RNA genome.  
There are 8 segments to the genome which encode 10 or 11 proteins.  These proteins 
include PB1, PB2 and PA which form the transcriptase complex.  The three 
transmembrane proteins HA (hemagglutinin), NA (neuraminidase) and M2 (an ion 
channel) are inserted through the lipid bilayer and are involved in entry and budding.  
The M1 or matrix protein underlies the lipid bilayer.  The nucleocapsid protein (NP) 
associates with the viral RNA.  Finally, there are two non-structural proteins NS1 and 
NS2.  NS1 is found in infected cells but is not a major part of the virion itself, and 
NS2 is found associated with virions in small quantities.  The hemagglutinin protein 
plays a key role in the binding and entry of the influenza virus.  The HA protein is 
cleaved into two parts during the viral life cycle which are termed HA1 and HA2.  HA 
1 is responsible for receptor binding and HA2 contains the fusion machinery.  A 
crystal structure is available which has greatly added to our understanding of viral 
fusion proteins.   
 The first stage in a viral lifecycle is the binding of the virus to the membrane of 
the host cell.  The influenza HA protein, more specifically HA1, is known to bind to 
sialic acid which triggers receptor mediated endocytosis in both a clathrin dependent 
and independent manner.  A crystal structure showing the binding hemagglutinin with 
its receptor sialic acid has been solved [1].  One can see that the sialic acid binds in a 
shallow depression at the top of the HA molecule.  The residues that the receptor 
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interacts with are conserved and not prone to antigenic drift.  NMR binding studies 
show that the binding of a single sialic acid residue is a low affinity event.  It has been 
concluded that several interactions are needed for strong virus binding.  The 
conformation of the sialic acid linkage controls the species tropism of the influenza 
strain.  Sialic acid can either be bound to the hydroxyl group of the third carbon of a 
galactose molecule to form an α2-3 linkage or to the hydroxyl group of the 6 carbon to 
form an α2-6 linkage.  Influenza strains that infect avian species have a preference for 
α2-3 linked sialic acid moieties.  Strains of influenza that infect humans have a 
preference for α2-6 linkage.  It has been observed that the mucins that are present in 
the upper respiratory tract of humans protect them from avian influenza strains by 
containing many sialic acids in the α2-3 linkage conformation which compete with 
cell surface receptors for viral binding.  Inhibition of the interaction between influenza 
HA and the cell surface sialic acid residues is being investigated as a possible 
therapeutic strategy [2].  As mentioned previously, the binding between one sialic acid 
residues and HA is weak, so a multivalent sialyloligosaccharide is required for a 
significant effect.  Although no pharmaceutical is yet available, multivalent 
sialyloligosaccarides and multivalent sialylmimetics show promise as new therapies.   
 Sialic acid residues can be found on both glycolipids and glycoproteins.  It has 
been established that gangliosides, or sialic acid residue containing glycolipids, are not 
essential for influenza virus infection [3].  In this study, cells lacking gangliosides 
called GM-95 cells were infected with influenza virus.  Although the sensitivity of the 
cells to several influenza strains were 2-4 times lower than that of wild types cells, it 
was clear that the lack of gangliosides did not prevent productive infection.  To 
determine whether a glycoprotein could be the receptor for influenza, a series of 
experiments were undertaken with cells that had a deficiency in receptor sialo-N-
glycans (Lec 1 cells) [4].  These studies show that although Lec 1 cells are still able to 
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undergo virus binding, fusion, and replication.  However, the virus is not able to 
initiate host cell infection which indicates a block during entry after the initial virus 
binding.  The authors further hypothesize that an N-linked glycoprotein is the receptor 
for influenza virus.   
MGAT1 
UDP‐GlcNAc:α3‐D‐mannoside β1,2‐N-acetylglucosaminyltransferase I 
(encoded by the gene MGAT1) controls the synthesis of hybrid, complex, and 
paucimannose N‐glycans in all eukaryotes [5].  It initiates the synthesis of these 
complex glycans by catalyzing the transfer of GlcNAc from UDPGlcNAc to the 
oligomannosyl acceptor Man5GlcNAc2-Asn [6].  The oligomannosyl acceptor is found 
on approximately 70% of cell-surface receptors and transporters with the motif Asn-
X/Ser/Thr (X≠ Pro) that are exposed to the lumen of the endoplasmic reticulum [7].  
The role of these complex N-glycans is so vital during development that an absence of 
the MGAT1 gene in mouse embryos is lethal [8], although it does not seem to be vital 
to life as evidenced by the existence of cells lines without a functioning  MGAT1 gene 
[9].   
Short Interfering RNA (siRNA) 
 Short interfering RNA are small (approximately 20-30 nucleotide base) non-
coding RNA sequences that can regulate genes and genomes [10].  A phenomenon 
related to siRNA, micro RNA (miRNA), was discovered in 1993 as an endogenous 
mechanism to control gene expression during development [11].  A key study in 2004 
found that exogenous dsRNA could be used to invoke similar mechanisms and 
specifically silence genes [12, 13].  The realization that dsRNA could be introduced to 
a cell exogenously to effect the expression of genes has had a profound impact on 
research in the biological sciences.  siRNAs are not only found during the 
developmental stages as they were originally found, they can also be derived from 
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viruses, centromeres, transposons, and endogenous genomic loci.  During the 
endogenous process, siRNAs are cut from the ends of longer double stranded RNAs 
by a protein called Dicer.  These siRNAs then induced the formation of a silencing 
complex named RISC.  In humans a RISC is composed of Dicer, TRBP and Ago-2 
[10].  This complex binds the siRNA and loads it into Ago-2.  Ago-2 cleaves the 
passenger strand, or the strand of the RNA duplex that will not be used to base pair to 
the target, and it is discarded.  After these steps have been accomplished the complex 
is active and can begin to influence gene expression.  Silencing is achieved by the 
active RISC by finding the target gene through Watson-Crick base pairing.  When the 
target gene has been located, it is degraded by Ago [10].  Another mechanism that 
RISC uses to modulate transcription is to associate with newly transcribed RNA, again 
through Watson-Crick base pairing.  This association promotes histone methylation  
and the formation of heterochromatin, a compact DNA structure.  The formation of 
heterochromatin effectively down regulates the transcription of the target gene [10]. 
To determine if the presence of N-linked glycoproteins were also important 
during the infection of human cells with influenza, I attempted to knock down the 
human equivalent of GnT1, called MGAT1.  GnT1 is the enzyme in hamster cells that 
was disrupted in the Lec 1 cells rendering them incapable of synthesizing mature N-
linked glycoproteins.  In order to achieve this goal, siRNA was utilized for transient 
modulation of gene expression and effect was monitored by Western blot, lectin 
binding and influenza infection.  An attempt to establish a cell line stably expressing 
siRNA to knock down the MGAT1 gene was also made.   
Materials and Methods 
Cells and virus 
 Cells utilized during this study, A549, HeLa, MDBK, and HEK-293T were 
obtained from ATCC.  The A549 cells were grown in Ham’s F12 media with 10% 
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Figure A1.1 Overview of the siRNA pathway (Carthew & Sontheimer, Cell, 2009). 
 
fetal bovine serum, 100 U/mL penicillin and 100 U/mL streptomycin.  All other cell 
types were grown in DMEM with 10 % fetal bovine serum, 10 mM HEPES, 100 
U/mL penicillin and 100 U/mL streptomycin.  Influenza (A/WSN/33) was obtained 
from ATCC and grown in MDBK cells inoculated at 0.01 MOI and harvested in 
DMEM containing 2% FBS, 10 mM HEPES, 100 U/mL penicillin and 100 U/mL 
streptomycin.  All cell culture reagents were purchased from Mediatech Inc. 
MGAT1 siRNA knockdown and influenza infection 
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 A549 cells were trypsinized and plated in 24-well plates in Ham’s F12 with 
10% FBS, 100 U/mL penicillin and 100 U/mL streptomycin, 24 hours prior to 
transfection.  A 25 pmol amount of the siRNA indicated was transfected with 0.5 µL 
of Lipofectamine 2000 (Invitrogen).  The RNA oligomers used were obtained from 
Ambion, and the Silencer Pre-designed siRNA database.  The sequences were 
obtained in annealed form and denoted as: 11388 (sense) 
GGCCUAUGACCGAGAUUUCtt (antisense) GAAAUCUCGGUCAUAGGCCtc; 
11481 (sense) GGGACAGCUUCAAGGCUUUtt (antisense) 
AAAGCCUUGAAGCUGUCCCtg; 11566 (sense) GGCUGAAUUGUCUGAAAAAtt 
(antisense) UUUUUCAGACAAUUCAGCCtt; and 289360 (sense) 
GAUCUCAAGAACGAUGACCtt (antisense) GGUCAUCGUUCUUGAGAUCtc.  
Approximately 48 hours after transfection, cells were assayed by Western blot for 
expression of MGAT 1 using a rabbit anti-MGAT 1 polyclonal antibody (Abgent) or 
infected with influenza A/WSN/33. 
MGAT1 stability test 
A549 cells were placed in a 24 well plate at 50% confluence.  After reaching 
70-80% confluence cycloheximide was added to the media at a concentration of 5 
µg/mL.  At regular intervals, cells were lysed and the lysate prepared for Western blot 
analysis. 
Plasmid construction and stable cell line generation 
Generation of stable cell lines utilized the pSuper.retro.neo system 
(Oligoengine).  Briefly, DNA oligomers were obtained (Oligoengine) based on the 
siRNA sequences 11481 and 289360 and were annealed.  The vector pSuper.retro.neo 
was linearized using BglII and HindIII and the DNA duplexes were ligated to the 
vector.  After bacterial transformation, clones were isolated and sequenced to verify 
the nucleotide sequence.  The pSuper.retro plasmids utilizing the 11481 sequence are 
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denoted as 24 and 26 and the plasmids utilizing the 289360 sequences are denoted as 1 
Results 
 In the initial experiments, a group of siRNA targeted to the MGAT1 gene were 
transfected to achieve a transient knockdown of the gene.  As shown in Figure A1.2, 
the level of MGAT1 expression after a single transformation of siRNA in A549 cells 
as determined by quantitative Western Blot was practically unchanged.   
 
Figure A1.2 Expression of MGAT1 after a single transfection of siRNA in A549 cells.  
The level of MGAT1 expression was determined by quantitative Western blot.   
 
Due to the fact that some proteins have longer half lives than others, it seemed from 
this experiment that the half life of MGAT1 was longer than the experimental time 
line. 
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In order to rectify that, a second transfection of siRNA was utilized as shown in Figure 
A1.3 
Figure A1.3  Expression of MGAT1 after two transfections of siRNA in A549 cells.  
The level of MGAT1 expression was determined by quantitative Western blot. 
 
However, a second transfection of siRNA did not seem to have an appreciable effect 
on the expression level of MGAT1 by any of the siRNA duplexes tested.  In order to 
determine whether a minimal amount of expression suppression on MGAT1 had an 
influence on the ability of influenza to infect A549 cells, an experiment was carried 
out that attempted to infect A549 cells that were transfected twice with siRNA, as 
shown in Figure A1.4.  In an attempt to determine the half life of MGAT1, which 
could be unusually long due to its nature as a transmembrane protein present in the 
medial-Golgi, a stability time course with cycloheximide was attempted.  
Cycloheximide is a inhibitor of protein biosynthesis in eukaryotic organisms.   
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Figure A1.4 Percentage of A549 cells infected by influenza WSN/33 after two 
transfections of siRNA.  NC and PC correspond to transfection of  the negative control 
and positive control siRNA and are expected to have no effect on influenza infection. 
 
It works by interfering with translocation during translation which blocks nascent 
peptide elongation.  By adding cycloheximide to the media in cell culture, protein 
synthesis is inhibited and therefore, the protein expression level monitored over time 
by Western blot is due to protein present before the addition of cycloheximide.  The 
results of a time course of the expression of MGAT1 in the presence of cycloheximide 
is shown in Figure A1.5. 
Discussion 
 As can be seen in Figures A2.1, and A2. 2 transient transfection of our siRNA 
duplexes was incapable of significantly decreasing MGAT1 expression.  At its 
greatest extent, the amount of knockdown was only 20%, which is not enough to have 
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Figure A1.5  Effect of cycloheximide on MGAT1 expression over a period of 12 
hours. 
 
a biological effect.  The lack of biological effect was confirmed by a lack of effect on 
fluorescein  labeled lectin binding (data not shown.)  Additionally, the transfection of 
siRNA had no effect on the infection of cells by influenza A/WSN/33.  To determine 
the stability of MGAT1 A549 cells were exposed to cycloheximide and the amount of 
MGAT1 expressed over time was monitored.  As shown in figure A2. 4 over a period 
of 12 hours no change in the amount of MGAT1 present in A549 cells was observed, 
indicating that the protein was exceptionally stable and might require the generation of 
a stable cell line to significantly be decreased with siRNA.  The MGAT1 expression in 
four stably transfected cells lines are shown in figure A2.5.  As in the transient 
transfection experiments, MGAT1 expression was only decreased by 20% in the most 
highly affected cell line.  Fluorescein labeled lectin binding to these cells showed no 
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difference between their ability to bind lectins and wild type cells lectin binding 
ability. 
Conclusions 
 Unfortunately, these experiments offer little insight to the effect of MGAT1 
expression on influenza infection inhuman cells.  There are several possible 
explanations for the difficulties encountered in these experiments.  First, it is possible 
that the siRNA sequences used did not efficiently knock down the desired gene 
MGAT1.  A recent literature search has revealed no reported accounts of successful 
knockdown of MGAT1 with these or any other siRNA sequences although successful 
studies have been done with Caenorhabditis elegans and perhaps the use of siRNA 
analogous to the sequences used in that study would be successful [5].  Additionally, 
these siRNA sequences could be toxic to the host cells, which would affect both 
transient and stable transfection.   Secondly, the MGAT1 protein seems to be 
unusually stable, which contributes to the difficulty in decreasing its expression.  I 
think future experiments should attempt to use different siRNA sequences.
 87 
REFERENCES 
 
1. Weis, W., et al., Structure of the influenza virus haemagglutinin complexed 
with its receptor, sialic acid. Nature, 1988. 333(6172): p. 426-431. 
2. Sun, X.L., Recent anti-influenza strategies in multivalent 
sialyloligosaccharides and sialylmimetics approaches. Current Medicinal 
Chemistry, 2007. 14(21): p. 2304-2313. 
3. Matrosovich, M., et al., Gangliosides are not essential for influenza virus 
infection. Glycoconjugate Journal, 2006. 23(1-2): p. 107-113. 
4. Chu, V.C. and G.R. Whittaker, Influenza virus entry and infection require host 
cell N-linked glycoprotein. Proceedings of the National Academy of Sciences 
of the United States of America, 2004. 101(52): p. 18153-18158. 
5. Shi, H., J. Tan, and H. Schachter, N-glycans are involved in the response of 
Caenorhabditis elegans to bacterial pathogens, in Functional Glycomics. 
2006, Elsevier Academic Press Inc: San Diego. p. 359-389. 
6. Kumar, R., et al., Cloning and expression of N-acetylglucosaminaltransferase-
I, the medial golgi transferase that initiates complex N-linked carbohydrate 
formation. Proceedings of the National Academy of Sciences of the United 
States of America, 1990. 87(24): p. 9948-9952. 
7. Lau, K.S., et al., Complex N-glycan number and degree of branching 
cooperate to regulate cell proliferation and differentiation. Cell, 2007. 129(1): 
p. 123-134. 
8. Ye, Z.Y. and J.D. Marth, N-glycan branching requirement in neuronal and 
postnatal viability. Glycobiology, 2004. 14(6): p. 547-558. 
9. Kumar, R. and P. Stanley, Transfection of a human-gene that corrects the Lec1 
glycosylation defect - evidence for transfer of the structural gene for N-
 88 
acetylglucosaminaltrasnferase-I. Molecular and Cellular Biology, 1989. 9(12): 
p. 5713-5717. 
10. Carthew, R.W. and E.J. Sontheimer, Origins and Mechanisms of miRNAs and 
siRNAs. Cell, 2009. 136(4): p. 642-655. 
11. Bartel, D.P., MicroRNAs: Genomics, biogenesis, mechanism, and function. 
Cell, 2004. 116(2): p. 281-297. 
12. Hutvagner, G., et al., Sequence-specific inhibition of small RNA function. Plos 
Biology, 2004. 2(4): p. 465-475. 
13. Mello, C.C. and D. Conte, Revealing the world of RNA interference. Nature, 
2004. 431(7006): p. 338-342. 
 
 
 89 
APPENDIX 2 
DIRECTED EVOLUTION OF STOFFEL FRAGMENT DNA POLYMERASE 
This work was done in the laboratory of Dr. D. Tyler McQuade in the Department of 
Chemistry and Chemical Biology at Cornell University.  It is presented here with his 
consent. 
Introduction 
Directed Evolution 
Directed evolution refers to a class of techniques that can be used to modify enzyme 
properties.  Mutant enzymes are used widely as reagents for chemical transformation, 
reagents for molecular biology, and as protein-based therapeutics [1].  According to a 
recent report, 60% of large scale commercial asymmetric syntheses involve at least 
one enzymatic or whole cell biotransformation [2].  Enzymatic reagents are used to 
make optically pure intermediates and products for the basic chemical, fine chemical, 
food science, agrochemical, and pharmaceutical industries [1].  Because wild-type 
enzymes often do not display the activity or the broad substrate scope needed for an 
academic or industrial application, these enzymes must first be mutated.  Two 
methods are available to mutate enzymes: rational design and directed evolution.  
Rational design relies on close inspection of protein models/crystal structures or a 
detailed understanding of active site structure and function to engineer a protein’s 
function [1].  This method works well in some cases, but can fail to alter behavior for 
many enzymes.  In addition, rational design may not effectively refine an enzyme’s 
activity, selectivity, etc.  Directed evolution (DE) selects proteins with the desired trait 
from large libraries of mutants in successive rounds.  DE improves activity, 
selectivity, and stability very effectively.  DE also enables the discovery of important 
residues away from the active site as well as quick access to structure activity 
relationships.   
 90 
 DE is a very effective method for refining a trait already exhibited by an 
enzyme [3, 4].  DE relies on the creation of a library of proteins consisting of mutants 
with multiple randomly placed mutations,[5] random mutations of a selected 
domain,[6] or saturation mutagenesis of a select number of amino acids [7].  DE’s 
power is revealed by high-throughput screening/selection [8].  Since many mutations 
are produced and selected in one round, DE’s success is predicated on how the 
genotype and phenotype are linked (Figure A2.1) [9].  
   
 
 
 
 
 
 
 Directed evolution can be reduced to three important factors: gene library 
creation, genotype-phenotype connection, and selection.  Protein libraries are 
generated at the genetic level.  The process typically starts by subjecting a gene to 
error prone PCR, which can be accomplished using normal or specially evolved 
polymerases under certain conditions [10].  The error rate can be tuned by altering the 
PCR conditions although most directed evolution approaches limit the mutation rate to 
only two or three mutations at the protein level [11].  Multiple rounds of selection are 
often performed on this library.  Once the error prone PCR library stops yielding 
proteins with improved properties, the selected members are then recombined using a 
technique such as DNA shuffling [12].  Recombination techniques typically consist of 
cutting a gene library into predetermined fragments and then ligating the fragments 
back together [12, 13].  The act of ligating concentrates beneficial mutations onto a 
Figure A2.1 Three Basic Methods to Link Genotype and Phenotype. 
One cell, one gene, one mutant 
One virus/virion,  
one gene, one mutant 
One emulsion droplet,  
one gene, one mutant 
A.  B.  C.  
Oil 
Water Gene Protein 
Gene  
Gene 
Protein 
Protein 
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single gene.  Many other strategies build off this basic theme but will not be discussed 
here [14].  
 The second feature of directed evolution is gene (genotype) and protein 
(phenotype) connection [1].  One-to-one correlation of the geneotype and phenotype is 
very important when selecting from a large library since proteins are not amplifiable.  
To ensure that a selected protein can be amplified, that protein must be associated with 
its easily amplifiable gene.  The two main methods of genotype-phenotype connection 
are in vivo and in vitro [8].  In vivo methods rely on the cell to link the gene and 
protein, whereas in vitro methods are cellular and rely on a virus,[15] virion,[16, 17] 
or emulsion[18] to hold the gene and protein together.   
In vivo methods rely on a whole cell to link one gene and one protein together.  
The process begins with the creation of a gene library that is then placed into an 
appropriate vector (eg. DNA plasmid).  The vector is then transformed into an 
appropriate host cell (ie. E. coli).  The vector is expressed within the cell and 
screening/selecting typically takes place without disrupting the cell [3]. 
 In vivo methods differ widely in the ways that successful enzymes are culled 
from unsuccessful enzymes.  Four techniques have been used to screen/select for 
successful enzymes in vivo: (1) Evolved enzyme yielding products that are 
colored/fluorescent [19], (2) Evolved enzyme replicating its own gene [20], (3) 
Evolved enzyme yielding a product linked to cell survival [21], and (4) Evolved 
enzyme creating a product that triggers transcription of a reporter gene [22].  The first 
three methods have been used successfully to evolve a number of protein classes, but 
all require a specialized substrate and as such none are general.  In vivo methods 
require whole cells, and neither the protein being evolved nor the substrate being used 
to screen/select should adversely affect cellular processes.  The adverse effects to cells 
can sometimes be used as the screen/select, but this is often not the case and these 
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adverse effects can provide misleading results.[23]   
Polymerases 
Polymerases are an important class of enzyme that can synthesize DNA from a 
DNA template, RNA from a DNA template, and DNA from RNA template [24, 25].    
Figure A2.2 SF crystal structure with motif a highlighted in black. 
 
These enzymes are crucial in key molecular biology experiments such as polymerase 
chain reaction (PCR),  DNA sequencing, and genotyping [26]. This importance has 
prompted researchers to use directed evolution (DE) to improve thermal stability, 
increase substrate promiscuity, and to both increase and decrease error rate in an effort 
to tailor a polymerase to a specific application [27, 28].  Additionally, directed 
evolution and rational design of polymerases with novel functions has identified 
important structure function relationships in polymerases. 
The mutability of the Thermus aquaticus (Taq) DNA Pol I active site is an 
example of structure function relationships that have been identified.  Loeb et. al 
found that all 18 residues associated with Motif A (605-617) are highly mutable 
except for residue 610 (Figure A1.2) [29].  The flexibility of the active site led to 
further experimentation with Motif A to see if substitutions could allow a Taq DNA 
Pol I to synthesize RNA.  Towards this goal, Loeb et. al made a library of 200,000 
Motif A mutants and screened for activity in vivo by complementation.  Twenty-three 
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mutants were identified that incorporated NTPs at a rate approaching 103 fold greater 
than that of wild-type Taq DNA Pol.   
Loeb’s experiments and results were an important breakthrough in the field of 
polymerase modification.  We believe that by building on this foundation, we can 
learn even more about polymerases.  Loeb’s work will allow us to verify our proposed 
polymerase directed evolution method.  Our system builds on that of Loeb by utilizing 
the increased flexibility inherent to in vitro systems.  Most importantly, our method 
allows us to directly select for polymerases that incorporate NTPs, as opposed to 
Loeb’s experiment which selected for complementation or incorporation of dNTPs 
followed by a screen for the incorporation of NTPs.  This subtle difference could 
result in our method producing different answers than those obtained by Loeb.  Also 
with Loeb’s system, very successful mutants would be selected against since NTPs, 
which  are available at a much higher concentration in vivo, would be incorporated 
into genomic DNA resulting in cell death [30].  Finally, our in vitro approach also 
allows us to screen more mutants than is practical for an in vivo system.     
Recently, phage display has been used to modify the properties of Stoffel 
Fragment (SF) polymerase to allow it to incorporate non-natural monomers.  SF, a 
truncated version of DNA pol from T. aquaticus, is missing the 5’→3’ exonuclease 
domain and has a number of crystal structures available [31].  Phage display uses 
bacterial viruses (phage) to connect genotype to phenotype [32].  The protein of 
interest is attached to one of the phage coat genes, typically one of the genes encoding 
for a protein found on the end of the phage, pIII (Figure A1.2).  Using a variety of 
methods the modified genome is expressed along with the other proteins to form a 
viable phage in a bacterial cell.  Once formed, the phage displays the protein of 
interest on its exterior while holding the genomic information in its interior.  The 
product of the reaction must “tag” the successful phage for evolution, which is 
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accomplished by Schultz and Romesberg by cleverly displaying two proteins on the 
surface of the phage (Figure A1.3) [6, 15].  One of the proteins serves as a “dock” for 
the substrate and the other protein is the protein being evolved.  Once the substrate has 
been attached to the phage, it will be tagged and carried through the selection if the 
displayed enzyme can catalyze bond-formation.  This phage method is spectacular, but 
difficult to implement and may suffer from geometric constraints if the protein active 
site and the substrate are not able to adopt an optimal orientation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This method was used to evolve SF Pol into a polymerase that could accept 
NTPs.  After 4 rounds of evolution, several SF Pol mutants were found that had a 103 
greater ribonucleotide incorporation efficiency of GTP, CTP, and ATP.  Romesberg 
went on to use this strategy to evolve SF Pol to accept 2'-OMe NTPs.  
Oligonucleotides containing 2'-OMe substitutions are desirable because they are more 
resistant to nuclease degradation.  After 4 rounds of selection from a library of 6.4 x 
(T28)ATCCCTGGAACCTCC 
(P50)TAGGGACCU 
(A) Phage particle with displayed polymerase and 
pIII-fused coiled-coil half.  
(B) Ribonucleotide substrate attachment with 
coiled-coil complement. 
(C) Biotin incorporation via active polymerases.  
(D) Immobilization of biotin-tagged phage particles 
with streptavidin beads. 
(T28)ATCCCTGGAACCTCC 
(P50)TAGGG 
Introduce primer-template 
(T28)ATCCCTGGAACCTCC 
(P50)TAGGG 
Biotin 
Capture biotin 
Biotin 
Supported 
streptavidin 
A. B. 
C. D. 
Displayed polymerase 
ATP, CTP, GTP, Biotin-UTP 
(T28)ATCCCTGGAACCTCC 
(P50)TAGGGACCU 
Figure A2.3. Romesberg and Schultz’s Phage Display Method for Directed 
Evolution of Polymerases. 
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107,  a SF Pol mutant was found that could incorporate 2'-OMe NTPs 104 times faster 
than the wild-type enzyme.  This mutant contained I614E and E615G mutations.  
Alternatively, the emulsion-based approach, reported by Griffith and Tawfik,  can 
evolve polymerases using in vitro transcription and translation reactions in a water-in- 
oil emulsion (Figure A2.4) [18].  As protein is expressed, the gene and protein are 
 compartmentalized together by the boundaries of an emulsion water droplet.  Ideally, 
one gene and multiple copies of a single mutant protein coexist per droplet.  This 
method, termed in vitro compartmentalization (IVC), has been adapted to the 
evolution of DNA polymerases by Holliger et al. in a process called 
compartmentalized self replication (CSR) [20].  Holliger et al. used 3’ mismatched 
primers to select for polymerases more tolerant of base mismatches [20].  As shown in 
Figure A1.3, the selection relied on the polymerase’s ability to replicate its own gene 
using primers with a terminal 3’ single mismatch.  
This method yielded a polymerase with relaxed specificity allowing it to 
bypass blocking lesions, perform PCR with all four nucleotide phosphorothioates and 
incorporate base dye-labeled nucleotides at a higher frequency.  Unlike phage display, 
Holliger’s CSR approach cannot be used to select for polymerases able to replicate 
templates with non-natural monomers.  
The overall goal of this research is to develop new methods to evolve 
Figure A2.4. Holliger’s Emulsion Approach for the Directed Evolution of a DNA 
polymerase. 
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polymerases and proteases for specific applications.  We have already achieved 
several key milestones that will allow us to evolve polymerases.  We selected the 
evolution of a polymerase as our first example because a number of other directed 
evolution methods have been used to evolve DNA polymerases.  This prior work will 
allow us to assess the performance of our approach through comparison to these other 
methods.  This section delineates the success we have had so far in (1) the 
implementation of IVC, (2) the expression of protein within emulsions, (3) the 
labeling of a gene by its expressed polymerase in emulsion, (4) the design and 
assembly of a library, and (5) the performance of a first round of directed evolution of 
SF Pol (Figure A2.5) 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
Implementation of IVC 
The in vitro expression of proteins within emulsions is a well-established area, 
which has been performed in several laboratories [33].  A water-in-oil emulsion is 
used in IVC to create a synthetic cell where a gene is expressed and confined with its 
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Figure A2.5. Overview of novel polymerase DE method 
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protein product in a single water droplet.  Despite the wide use of IVC, stable 
emulsion formation can be difficult due to variations in stirring apparatus and 
surfactant purity [34].  Before importing IVC, we investigated several emulsion 
formulations to determine which provided a stable emulsion capable of synthesizing 
protein. 
A water-in-oil emulsion consists of small water droplets (1-50μm in diameter) 
suspended in an oil phase. The emulsion is created by mixing surfactant, oil, and a 
small amount of water together.  We examined several formulations from the literature 
[18, 35-38] and found that a mixture of 4.5% w/w Span 80 and 0.5% w/w Triton X-
100 in mineral oil gave stable emulsions.  The organic phase is prepared by dissolving 
Span 80 and Triton X-100 in mineral oil and cooling on ice.  The aqueous phase 
consists of the gene to be expressed and EcoPro, an in vitro T7 RNA polymerase 
transcription and an E. coli translation extract (Novagen).  The emulsion is formed by 
mixing the oil phase with a homogenizer at 6,500 rpm and slowly adding the aqueous 
phase.  This method produced an emulsion stable for greater than 4 hours at 37˚C. 
Not only did this formulation provide a stable emulsion, it formed droplets of 
an appropriate size for protein synthesis.  If the aqueous droplets are too large, several 
genes will be present in each reverse micelle leading to scrambling of genotype and 
phenotype.  If the droplets are too small, protein synthesis could be limited by the 
absence of components.  Statistical analysis of our emulsion from optical microscope 
images (not shown) revealed that our average droplet diameter was 2±1 μm.  This size 
range is comparable to those found in the literature for IVC systems [18, 37]. 
Expression of proteins in emulsion 
To verify that our emulsion formulation was capable of supporting protein expression, 
we charged a 50μL EcoPro transcription and translation reaction with 1μg of DNA 
template encoding S•Tag labeled DNA polymerase I from E. coli and another reaction 
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with 100ng of template, a negative control containing no template DNA was also 
assembled.  Emulsions were made as previously described and incubated at 37˚C for 2 
hours.  The emulsion was then broken by adding 200 μL of ice cold TE buffer and 1 
mL of water saturated ether.  After the phases were separated, the aqueous phase was  
washed several times with ether.  A modified S•Tag assay [39] (Novagen), which is 
based on the assembly of a ribonuclease from the supplied S•Tag grade protein and the 
S•Tag from the expressed protein, was used to assess whether protein was synthesized 
in the emulsions.  The assay reaction containing ribonuclease substrate (polyC), S•Tag 
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Figure A2.6 The production of protein within the water-in-oil-emulsion.   
Using the modified S·Tag assay, CMP monomer production from the 
reconstituted ribonuclease S protein was used to indicate the presence or 
absence of protein synthesized.  The DNA template used was plasmid, 
supercoiled DNA encoding a protein with the S·Tag at the C-terminus.  
The graph shows a representative experiment. 
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grade protein, sterile water, ribonuclease buffer, and aqueous phase from the emulsion 
was assembled for each of the three reactions.  A zero time point was removed from 
the assay reaction and quenched with 25% ice-cold tricholoroacetic acid (TCA).  
Assay reactions were then incubated at 37˚C  and aliquots were taken at 3 and 8 
minutes and quenched.  The quenched aliquots were incubated on ice and spun in a 
cold microcentrifuge to precipitate and pellet any remaining polyC ribonuclease 
substrate.  The absorbance of the supernatant was measured at 280nm and used to 
determine how much CMP was liberated after reaction with the assembled 
ribonuclease.  As shown in Figure A1.5, the protein synthesized in emulsion 
assembled with the supplied S•Tag grade protein, digested the polyC substrate, 
releasing CMP and caused an increase in absorbance at 280nm over time.  These 
results indicated that our emulsion system was capable of synthesizing protein.     
Labeling of a gene by its expressed polymerase in emulsion 
Recently, Romesberg identified a SF mutant, I614EE615G, using directed 
evolution and phage display, which is capable of making short strands of RNA.  To 
determine whether a polymerase could be expressed in an active form in our emulsion 
system, we decided to make the SFI614EE615G mutant and try to recover its gene 
from our system (Figure A1.5 and A1.6). 
The SF DNA Pol gene was amplified from pWB254b (ATCC#69244) by PCR 
utilizing primers encoding Eco RI and Hind III restriction sites.   The gene was then 
Figure A2.7. The Successful Approach SF Polymerase Selection. 
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cloned into E. coli expression vector pET-29c(+) (Novagen) and confirmed with DNA 
sequencing.  The gene was then mutated using PAGE purified oligonucleotide primers 
encoding the mutations I614EE615G and the QuickChange Mutagenesis kit 
(Stratagene).  The mutation was confirmed with DNA sequencing.  
To assess the activity of our constructed SF DNA Pol mutant, we attempted to 
recover its gene from our system.  First, the SFI614EE615G gene was amplified by 
PCR from its vector using specially modified primers (Table A1.1).  The forward 
primer of this set was based on the commercially available pETUP primer (Novagen) 
which allows for the appropriate amount of space between the end of the gene and the 
T7 promoter.  The reverse primer was based on the T7 terminator primer (Novagen).  
To these primer sequences (suggested by the manufacturer), we added regions to the 5' 
end analogous to the sequences used in ligation independent cloning.  These sequences 
began with a T on the 3’ end and continued with 20 bp utilizing only A, C, and G.   
 
Table A2.1.  Sequences of the specialized primers that allow for partial digestion of 
the SF gene. 
Primer Sequence (5'-3') 
Forward 
Primer 
AAC GAA GAC CAC GAC AAG ATA TGC GTC CGG CGT 
AGA 
Reverse 
Primer 
AAC GAA GAG GAG AAG ACC AGT GCT AGT TAT TGC 
TCA GCG G 
The gene is then digested in the 3'-5' direction with T4 DNA polymerase in the 
presence of dATP which stops the digestion at the first adenine encountered.  The 
digested SFI614EE615G gene was then purified and used to program an in vitro 
transcription and translation reaction.  One microgram of digested DNA was added to 
a 50μL reaction containing 35 μL EcoPro extract, 2μL 5 mM methionine, and 5 μL 10 
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mM biotin-16-UTP (Roche Applied Science).  The in vitro transcription and 
translation reaction was then added to an oil and surfactant mixture to make an 
 emulsion.   
After incubation for 2 hours at 37˚C, the reaction was stopped and emulsion broken by 
the addition of 200 μL of ice cold TE buffer and 1 mL ice cold water saturated ether.  
The broken emulsion was centrifuged for 5 minutes to separate the aqueous and 
organic phases and the aqueous phase was washed twice with 1 mL ice cold water 
saturated ether.  The reaction was then purified to remove unincorporated biotin-16-
UTP.  The DNA was then exposed to Streptavidin Paramagnetic Particles (SA-PMPs, 
Promega) and incubated for 30 minutes at room temperature.  The SA-PMPs were 
washed three times with 300 μL sterile water and resuspended in 10 μL sterile water.  
PCR is then used to amplify any captured, biotinylated genes.  As shown in Figure 5, 
PCR product was obtained from our reaction indicating that the expressed polymerase 
was active.  The negative control, which did not contain biotin-16-UTP, showed no 
PCR product since it was unable to label its own gene and survive the streptavidin 
column. Therefore, our gene construct was able to express the SFI614EE615G protein 
in an active form that labeled its own gene by the incorporation of biotin-UTP.   
1 2 3 
Figure A2.8.  Agarose gel of biotin incorporation by SF Pol in emulsion.  
Lane 1: 1 kb DNA ladder (Promega).   
Lane 2: Negative control.  Shows with no biotin-UTP SF gene is not labeled nor 
recovered a streptavidin resin.   
Lane 3: SFI614EE615A. A band shows SF Pol incorporates biotin into its gene 
by polymerizing RNA, allowing for amplification from the streptavidin resin.  
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Construction of a SF library for directed evolution 
The first step in a directed evolution experiment is to design and make a DNA 
library.  We chose to use saturation mutagenesis to completely randomize residues 
611-615 in the Motif A of Stoffel Fragment.  This region is known to interact with the 
incoming nucleotide triphosphate during DNA synthesis.  In other literature examples 
of the evolution of Stoffel Fragment to accept NTPs or 2'-OMe NTPs, mutations have 
been found in this region.  Therefore, it is an ideal place to start to change SF Pol so 
that it can accept ribonucleotide monomers. 
 
Table A2. 2.  Mutants of Taq DNA Pol/SF found in Motif A that allow incorporation 
of NTPs or 2'-OMe NTPs 
 
Activity Mutations of most active 
clones 
Reference 
NTP incorporation I614K, A608:I614N, 
I614N:L616I, 
A608D:E615D 
[30] 
NTP incorporation I614T:E615G, 
A597T:E615G 
11 
2'-OMe NTP 
incorporation 
I614E:E615G [40] 
 
The SF library was made using an oligonucleotide primer that encoded NNS at 
residues 611-615.  This allowed complete randomization to all 20 amino acids, 
reduction in bias due to the degeneracy of the genetic code, and a reduction in the 
number of possible stop codons.  PCR and the randomized primer were used to 
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amplify approximately half of the gene.  The remainder of the gene was amplified 
with non-degenerate primers so that there was a region of overlap consisting of 
approximately 20 bp.  Single overlap extension PCR was then used to reassemble the 
gene (data not shown). 
First round of directed evolution of SF Pol 
The assembled library (see 4, above) was digested with T4 DNA polymerase 
as mentioned previously.  A 50μL in vitro transcription and translation reaction was 
programmed with 1 μg of digested library.  After breaking the emulsion and exposure 
of the aqueous layer to streptavidin paramagnetic particles, PCR was used to amplify 
any labeled sequences. These sequences were selected because they were able to label 
their own DNA with biotin, indicating that they could polymerize RNA.   
These sequences were amplified and blunt ligation (Perfectly Blunt Cloning Kit, 
Novagen) was used to clone them into the pETBLUE-2 vector. Following 
transformation into chemically competent cells, individual colonies were grown, their 
  1       2      3      4 
Figure A2.9.  Agarose gel of successful first round of SF Pol directed 
evolution.  
Lane 1: 1 kb DNA ladder.   
Lane 2: Positive control, SFI614EE615G. A band shows mutant can label its 
own gene. 
Lane 3: Negative control. No band shows that SFI614E E615G gene is not 
recovered in absence of biotin-16-UTP.   
Lane 4: SF Pol library.  A band shows that some mutants from the DNA 
library are able to label their own gene with biotin-16-UTP. 
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plasmids isolated and subjected to DNA sequencing.  Examination of approximately 
60 colonies revealed several interesting sequences.  Foremost, the sequence obtained 
by Romesberg and known to incorporate 2'-OMe NTPs was found, indicating our 
method can isolate polymerase mutants capable of synthesizing non-natural oligomers.  
Other interesting mutants, different from those observed by Loeb and Romesberg, 
included sequences with a similar structural motif of an acidic residue at position 614 
or 615 and a small residue at the other position [30].  Clearly, these mutants could 
encode polymerases that have equal or greater ability to incorporate NTPs then 
previously reported mutants.   
Table A2.3. New mutants with the potential to polymerize NTPs. 
 
 
 
 
 
 
 
 
Conclusions 
We have developed a new selection method for polymerase activity using an 
emulsion-based system.  We have confirmed that a stable emulsion can be formed that 
allows for the expression of active protein.  We have further proved that our system 
can recover genes from active polymerases.  Further work including an assessment of 
the mutants from our first round of evolution, and subsequent rounds of evolution is 
definitely warranted. 
 
Mutant 
Designation 
611 612 613 614 615 
SLRIV256B12 I A M E C 
SLRIV256C1 E W R H E 
SLRIV256D8 K F G C E 
SLRIV256D12 A R E D L 
SLRIV264D8 R N Y E G 
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